

Sunday 17 July
10:15-12:15

SUSA01 Defining the Benefits of NNRTI Treatment: New Data, New Parameters
Commercial Satellite

Venue: Session Room 2

Time: Sunday 17 July, 10:15-12:15

Although NNRTIs as a class have been available for over a decade, new data continue to emerge on older as well as newer agents. This symposium will consider both the current and potential future role of nevirapine particularly in light of the recent availability of data on the nevirapine/tenofovir/emtricitabine combination from large randomised studies, and the increasing availability of long-term outcomes data from cohort studies in the real-world setting. As our understanding of the clinical and metabolic impact of HIV infection and its treatment continues to grow, the number of parameters by which we can measure the success of treatment has also expanded. The symposium will, therefore, go on to consider the clinical relevance of some of these parameters, including the potential roles of ultrasensitive HIV-RNA detection methods (<1–2 copies/mL), pre-treatment tropism with regard to outcomes of non-CCR5 antagonist-based regimens, and alterations in vitamin D levels.

10:15 **Welcome and introduction**

10:20 **Nevirapine today: what do we know?**

10:45 **Nevirapine tomorrow**

11:15 **Defining success in HIV treatment: should we broaden the parameters?**

SUSA02 Controlling the HIV Epidemic, the Promise of ARV-based Prevention
Non-Commercial Satellite

Venue: Mini Room 1

Time: Sunday 17 July, 10:15-13:15

Recent successes in microbicides, pre-exposure prophylaxis (PrEP), test and treat, and vaccines are encouraging developments in AIDS research and give reason for optimism that the epidemic might be controllable in some populations. To make full use of new knowledge and technology, efforts at HIV prevention must be coordinated and focused on clearly defined goals. The meeting and discussion will argue the case for making HIV epidemic control the goal of prevention, and for assembling the required expertise, and deploying essential resources, to conduct needed studies. A variety of studies of prevention packages are now being planned or are underway.

- One focus of the meeting will be review of these studies and consideration of what else may be needed in advancing the prevention agenda.

- Another focus will be presentation and discussion of a proposal to conduct a pilot study of large scale community based combination prevention to be done at one or 2 sites to be identified, using existing infrastructure. This proposal is intended to illustrate what types of research might be feasible in community settings at reasonable cost.

We foresee the workshop serving as a first step in the development of a consensus statement on the need to ramp up efforts to use ARV-based combination prevention (such as test and treat, microbicides, and PrEP) for community-level control of HIV infection. Such efforts require consultation and coordination among industry, governments, international agencies, research institutes, and community groups. Combination prevention studies must be undertaken in a wide variety of settings and make use of, as well as strengthen, existing infrastructure for testing, monitoring, and treating people living with or at risk of HIV infection. The "3 by 5" initiative launched in 2003 by WHO and UNAIDS had an enormous impact on advancing access to ARV throughout the world, and we believe that the time is right for the development of a multi-stakeholder consensus statement on the need to expand efforts to use ARV-based combination prevention to achieve community-level control of HIV infection.

10:15 **Introduction: Overview of new advances and remaining challenges in the HIV prevention field**

10:25 **Perspectives from the different disciplines to inform the design, set-up and conduct of combination prevention studies at community level**

10:25 **1- Study Design and Analysis**

10:40 **2- Clinical Considerations**

10:55 **3- Modelling**

11:10 **4- Community Perspective**

11:25 **Coffee Break**

11:35 **Presentation of the pilot proposal**

12:05 **Moderated Roundtable - "Controlling the epidemic- the promise of ARV based prevention"**

13:00 **Wrap-up / Conclusions / Next steps towards the development of a consensus statement**

SUSA03 The Role of Communities in the Elimination of Pediatric HIV and AIDS - Bringing Program Implementers and Researchers Together
Non-Commercial Satellite

Venue: Mini Room 2
Time: Sunday 17 July, 10:15-12:15

In order to reach the virtual elimination of pediatric HIV and AIDS, research on community-oriented models and approaches that work should inform the implementation of prevention of vertical transmission of HIV ("PMTCT") programs. However, donors, policy makers, non-profits and community-based organizations often have a limited understanding of how to translate research into action, making it difficult for these groups to inform policies and programs. Likewise, program implementers have an important role to play in informing the research agenda for community-based interventions.

This moderated panel discussion will bring researchers and implementers together to discuss cutting edge research and emerging findings on community models and approaches that work as well as results and lessons learned from programs that have been informed by evidence.

The session will aim to achieve the following objectives:

Identify strategies for translating research into practice;
Identify research priorities in the role that communities play in working towards the elimination of pediatric HIV and AIDS.

Sunday 17 July 12:30-14:30

SUSA04 Learning from Our Experience: A Lifetime Focused on Women Living with HIV

Commercial Satellite

Venue: Session Room 2
Time: Sunday 17 July, 12:30-14:30

Chaired by
Dr Sharon Walmsley, Canada

Case Study 1: Experiences from the Childbearing Years
Led by Dr Sharon Walmsley
From Menstruation to Menopause: The Childbearing Years
Professor Antonella d'Arminio Monforte
San Paulo Hospital
Milan, Italy

Case Study 2: Growing Older with HIV
Led by Dr Sharon Walmsley

Neurocognitive Changes and the Emotional Impact of HIV
Professor Gabriele Arendt
University of Düsseldorf
Germany

Life Begins at 40: Ageing Well with HIV
Dr Adriana Ammassari
National Institute for Infectious Diseases
Rome, Italy

12:30 **Case Study 1: Experiences from the Childbearing Years**
12:30 **From Menstruation to Menopause: The Childbearing Years**
12:30 **Case Study 2: Growing Older with HIV**
12:30 **Neurocognitive Changes and the Emotional Impact of HIV**
12:30 **Life Begins at 40: Ageing Well with HIV**

SUSA05 GPP in Action: Introducing the 2nd Edition of Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials and Examples of its Implementation in Current Research

Non-Commercial Satellite

Venue: Mini Room 2
Time: Sunday 17 July, 12:30-14:30

The purpose of this session is to launch the 2nd edition of the GPP Guidelines, and to discuss examples of GPP already being used in the field. The session will provide a brief overview of the 2nd Edition of the GPP Guidelines, followed by a series of short presentations from research teams on their experiences with implementing aspects of the GPP guidelines, and then a moderated discussion with the panelists and the audience. This session is for trial funders, trial sponsors, research team members, community stakeholders, and all other stakeholders of biomedical HIV prevention research.

SUSA06 From Proof to Delivery: Scaling up HIV Prevention for Women. The Challenge of Delivering the First Microbicide in Africa

Non-Commercial Satellite

Venue: Mini Room 3
Time: Sunday 17 July, 12:30-14:30

Topical, and interactive debate on the challenges of introducing the first ARV-based vaginal microbicide for women in South Africa. Since the landmark results of CAPRISA 004 showing that tenofovir gel used as a vaginal microbicide could help to protect women from HIV, there has been a palpable urgency to pursue licensure and expedite steps towards production and the delivery of this new technology for women. This satellite will explore the challenges of introducing a new health technology that can help empower women in their sexual choices. Leading

practitioners from government, donors, product development and the community advocacy will discuss the journey from scientific proof to a microbicide in the hands of women. While South Africa leads the way as the first country to provide efficacy results, the discussion will also focus on how other African nations can benefit from this new technology for women, particularly in settings where women now constitute

SUSA17 Treatment for Prevention: Game Changer or Fantasy?
Non-Commercial Satellite

Venue: Mini Room 4

Time: Sunday 17 July, 12:30-14:30

In light of the recent groundbreaking study HPTN 052, which showed that HIV transmission can be reduced by up to 96% if HIV-positive people start antiretroviral treatment early, the path to reversing the epidemic is clearer than ever. Join the dialogue with a panel of experts on making the new UNAIDS initiative 15 by 15 a reality. Getting 15 million people on treatment by 2015 is achievable.

Sunday 17 July
14:45-16:45

SUSA07 Premature Ageing with HIV: Translating Science into Clinical Practice
Commercial Satellite

Venue: Session Room 2

Time: Sunday 17 July, 14:45-16:45

The satellite symposium organised and sponsored by ViiV Healthcare at IAS will explore the new and increasing management challenges associated with living and ageing with HIV. The faculty will provide an overview of the current evidence and scientific thinking on processes that result in premature ageing in patients with HIV and also discuss strategies and resources which can be utilised today to address some of the associated management challenges.

An important element of the symposium will be to make it patient-focused and clinically relevant for the attending audience (as well as scientifically interesting); therefore, there will be involvement of a patient faculty member and inclusion of case studies where appropriate. In addition, to maximise audience participation and interactivity during the symposium we will use a keypad voting system throughout, and have included time for a dedicated Q&A session during the course of the symposium.

- 14:45 **Chair's introduction: Ageing with HIV: A new and evolving era in patient management**
- 15:00 **Inflammation and ageing on cART: What is the virus doing?**
- 15:25 **Patient comment**
- 15:30 **Inflammation and ageing on cART: What does this mean for management?**
- 15:55 **Patient comment**
- 16:00 **Current approaches and resources to help address the challenge in everyday clinical practice**
- 16:15 **Panel discussion, Questions and answers**
- 16:40 **Chair's summary and close**

SUSA08 Prevention Technologies: Gender and GIPA. Complement or Collision?
Non-Commercial Satellite

Venue: Mini Room 1

Time: Sunday 17 July, 14:45-16:45

Panel discussion and followed by interaction from the floor

SUSA09 HIV Vaccines and the Prevention Revolution: Shortening the Path to the End of the Epidemic
Non-Commercial Satellite

Venue: Mini Room 2

Time: Sunday 17 July, 14:45-16:45

HIV vaccine research has progressed further and faster in the past five years than at any time in the 28-year history of the epidemic. This new and highly promising era in HIV vaccine research is being guided by the Scientific Strategic Plan (Plan) of the Global HIV Vaccine Enterprise (Enterprise), a global collaboration of independent research, funding, policy and advocacy organizations working to address and overcome the most significant obstacles to developing a preventive HIV vaccine.

The Plan calls for faster, more efficient and more scientifically rich clinical trials to transform the achievements of the last five years into improved vaccine candidates for testing. In this interactive satellite session, Enterprise partners will discuss the future of HIV vaccine research and development, spanning from the latest discoveries in immunogen design to the effect of the changing landscape of multiple prevention modalities on efficacy trials. Specifically, this satellite will feature discussion on

- 14:45 **Introduction: Where are we in HIV vaccine research?**
 - 15:05 **Latest developments in basic research and clinical trials**
 - 15:25 **Enabling Issues for Combination HIV Vaccine Trials**
 - 15:45 **Moderated Panel and Q&A**
-

SUSA10 Plugging the Leaky Cascade: MSF and Others Discuss Treatment Strategies and Innovations Needed to Reach More People with ART and Keep Them in Care

Non-Commercial Satellite

Venue: Mini Room 3

Time: Sunday 17 July, 14:45-16:45

In light of the latest science that HIV treatment reduces new infections, 'plugging the leaky cascade' become all the more critical. Ten years into providing antiretroviral treatment in developing countries, Médecins Sans Frontières (MSF) and other providers continue to grapple with the challenge of losing people between HIV testing and ART initiation, as well as supporting people to remain adherent and in care once they begin ART. Panelists will discuss operational experiences as well as new treatment strategies and innovations that are needed in order to realize the full benefits of ART in reducing population-level HIV deaths, illness, and new infections.

- 14:45 **Welcome**
- 14:48 **"The first step is admitting you have a problem"**
- 14:58 **The role of treatment literacy and PLWHA empowerment**
- 15:08 **MSF's experience plugging the leaky cascade**
- 15:18 **Strategies to improve retention in pre-ART care**
- 15:28 **Beyond the PHC level**
- 15:38 **Taking Community ART Groups to scale in Mozambique**
- 15:48 **Call to action: need new tools and strategies needed**
- 15:58 **Q&A and discussion: what else can we try?**

SUSA11 Operational Challenges Scaling up PMTCT and Linkage to Care

Non-Commercial Satellite

Venue: Mini Room 4

Time: Sunday 17 July, 14:45-16:45

This satellite will be an opportunity to discuss and debate on issues related to the implementation of Prevention of Mother-to-Child Transmission interventions, and how such interventions/programmes can be linked to primary care services in resource-limited settings.

Sunday 17 July
17:00-19:00

SUSA12 Portrait of the HIV Patient: Understanding the Prevalence and Management of Co-morbidities

Commercial Satellite

Venue: Session Room 2

Time: Sunday 17 July, 17:00-19:00

- 17:00 **Opening remarks**
- 17:05 **Prevalence of Co-morbidities Among the HIV Positive Population**
- 17:25 **Considerations for HIV/HCV Co-infection**
- 17:50 **CV and Metabolic Co-morbidities with HIV**
- 18:15 **The Patient and the Doctor: Their Combined Role in Care**
- 18:40 **Panel discussion and Closing remarks**

SUSA13 HIV Serodiscordant Couples: Opportunities and Challenges for Testing and Counselling, Prevention and Treatment

Non-Commercial Satellite

Venue: Session Room 3

Time: Sunday 17 July, 17:00-19:00

WHO is releasing guidelines for testing and counselling of couples. In light of new trial data demonstrating the effectiveness of ART for prevention of transmission in serodiscordant couples, this satellite will provide the forum to discuss a range of issues related to HIV serodiscordance, including the operational and ethical challenges of this new prevention opportunity.

SUSA14 The Cutting Edge: What's New in Male Circumcision

Non-Commercial Satellite

Venue: Mini Room 1

Time: Sunday 17 July, 17:00-19:00

For more than 35 years, Jhpiego has pioneered innovative, low-cost, lifesaving solutions for today's global health concerns, including the prevention of HIV/AIDS. One of the most effective tools that exists today is male circumcision (MC).

Compelling evidence indicates that MC can reduce the risk of female-to-male transmission of HIV by approximately 60%. MC provides a greater protective benefit than any potential vaccine studied to date. Modeling suggests that rapid scale up of MC to 80% of adult males in East and Southern Africa would avert 4.1 million new infections by 2025. Further, there is evidence that female partners of circumcised men have lower rates of cervical cancer and certain sexually transmitted infections.

Join Jhpiego and its partners from CDC, WHO and USAID for conversation and refreshments.

17:00 **Starting at the Beginning: Early Infant MC; by Tigistu Adamu, HIV/AIDS Technical Advisor, Jhpiego**

17:00 **Serving Adults: Adult Male Circumcision Devices; by Jason Reed, Medical Epidemiologist, Centers for Disease Control and Prevention**

17:00 **WHO Approval Process for Medical Devices; by Tim Farley, World Health Organization**

17:00 **Male Circumcision Campaigns: Matching Supply and Demand; by Emmanuel Njuehmeli, Senior Biomedical Prevention Advisor, USAID**

SUSA15 Elimination of Mother-to-Child Transmission of HIV: Measuring the Effectiveness of National PMTCT Programmes
Non-Commercial Satellite

Venue: Mini Room 2

Time: Sunday 17 July, 17:00-19:00

Background. Many countries have been rapidly scaling up coverage of PMTCT programs, with substantial support from PEPFAR and Global Fund, and are now introducing more effective antiretroviral regimens based on new 2010 WHO PMTCT ARV guidelines. There is international momentum for the elimination of mother-to-child transmission, with overall targets to reduce new paediatric infections by 90% and to reduce population-level mother-to-transmission rate to less than 5%; Regional frameworks for MTCT elimination are under development and national targets are now being set to achieve low vertical transmission rates (eg. <5% transmission at 18 months) and high HIV-free survival alongside improving maternal and child health.

Measuring and monitoring the impact and effectiveness of national PMTCT programmes has been prioritized by the international Interagency Task Team on Preventio

SUSY01 Conference Orientation Session
Symposium

Venue: Mini Room 3

Time: Sunday 17 July, 17:00-19:00

Co-Chairs: David Galetta, South Africa
Gcebile Ndlovu, South Africa

For community delegates and all first-time conference attendees, this session will provide practical tips on navigating the conference in a meaningful way. A valuable component of the session will be presentations from Track Chairs who will give an overview of their respective tracks and suggest sessions that may hold interest to new and community delegates.

17:00 **Opening and overview**
G. Ndlovu, South Africa
D. Galetta, South Africa

17:10 **Welcome to Rome**
S. Vella, Italy

17:15 **Overview and highlights of Track A: Basic Sciences**
G. Silvestri, United States

17:25 **Overview and highlights of Track B: Clinical Sciences**
P. Salif Sow, Senegal

17:35 **Overview and highlights of Track C: Prevention Science**
C. Beyrer, United States

17:45 **Overview and highlights of Track D: Operations and Implementation Research**
S. Sai Raghavan, India

17:55 **Introduction to networking and information session**
D. Galetta, South Africa
G. Ndlovu, South Africa

18:00 **Networking and information gathering**
G. Ndlovu, South Africa
D. Galetta, South Africa

SUSA16 Challenges in Paediatric ARV Formulations
Non-Commercial Satellite

Venue: Mini Room 4

Time: Sunday 17 July, 17:00-19:00

This satellite session will look into both issues pertaining to formulations themselves for infants and children, along with supply issues (e.g. procurement of paediatric ARVs).

Sunday 17 July

19:30-20:30

SUPL01 Opening Session

Plenary

Venue: Session Room 1

Time: Sunday 17 July, 19:30-20:30

Doors Open at 18:45. Musical performance will begin at 19:10

19:30 **Welcome to IAS 2011**

E. Katabira, Uganda

S. Vella, Italy

19:35 **Welcome from the Istituto Superiore di Sanità**

E. Garaci, Italy

19:40 **Address from the Local and National Authorities**

20:00 **Community Welcome**

F. Von Schloesser, Italy

20:10 **Keynote Address**

M. Sidibé, Switzerland

Monday 18 July

08:55-10:30

MOPL01 Monday Plenary Session

Plenary

Venue: Session Room 1

Time: Monday 18 July, 08:55-10:30

Co-Chairs: Thomas Quinn, United States

Celia DC Christie-Samuels, Jamaica

Julio Montaner, Canada

08:55 **Award Presentation: Women, Girls and HIV Investigator Prize**

09:00 **The Changing Face of HIV Vaccine Research**

G. Nabel, United States

09:25 **Managing HIV Treatment in 2011**

G. Di Perri, Italy

09:50 **The Combined Approach to Preventing HIV Infection**

R. Shattock, United Kingdom

Monday 18 July

11:00-12:30

MOAB01 Complications of HIV and ART

Oral Abstract Session

Venue: Session Room 1

Time: Monday 18 July, 11:00-12:30

Co-Chairs: Cristina Mussini, Italy

Yazdan Yazdanpanah, France

11:00 **Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents**

R. Bedimo, S. Zhang, H. Drechsler, P. Tebas, N. Maalouf
United States

11:10 **Coronary artery calcification is associated with femoral but not with lumbar spine mineral density**

A. Bellasi¹, S. Zona¹, G. Orlando¹, F. Carl¹, S. Cocchi¹, G. Ligabue¹, V. Rochira¹, P. Bagni¹, P. Raggi², G. Guaraldi¹
¹Italy, ²United States

11:20 **Prevalence and risk factors for HIV associated neurocognitive disorders (HAND), 1996 to 2010: results from an observational cohort**

P. Balestra, V. Tozzi, M. Zaccarelli, R. Libertone, G. Cataldo, G. Liuzzi, S. Menichetti, M. Giulianelli, P. Narciso, A. Antinori
Italy

11:30 **Examining the impact of CNS penetration effectiveness of combination antiretroviral treatment (cART) on neuropsychological outcomes in persons living with HIV: findings from the Ontario HIV Treatment Network (OHTN) cohort study**

S.B. Rourke, A. Carvalhal, A.R. Zipursky, T. Bekele, J. McCombe, A. Rachlis, E. Collins, M.J. Gill, J. Raboud, A. Burchell
Canada

11:40 **HIV-related predictors and outcomes in 275 liver and/or kidney transplant recipients**
G. Beatty, B. Barin, L. Fox, J. Odum, S. Huprikar, M. Wong, J. Diego, E. Blumberg, D. Simon, J. Light, M. Yin, C. Davis, D. Jayaweera, D. Hardy, M. Ragni, L. Johnson, A. Subramanian, V. Stosor, K. Brayman, K. Pursell, R. Zhang, G.M. Lyon, A. Taege, J. Feinberg, B. Weikert, P. Stock, M. Roland
United States

11:50 **Moderated discussion**

MOAA01 Reservoirs and Mechanism of Disease Progression

Oral Abstract Session

Venue: Session Room 2

Time: Monday 18 July, 11:00-12:30

Co-Chairs: Andrea Savarino, Italy
Andrea Cossarizza, Italy

11:00 **Differential impact of IL-7 and IL-15 on HIV reservoir persistence**
C. Vandergeeten, S. Da Fonseca, I. Sereti, M. Lederman, R.-P. Sekaly, N. Chomont
United States

11:10 **The PI3K signaling pathway is critical for HIV integration in latently infected resting CD4+T-cells**
S. Saleh, P. Cameron, G. Sallmann, A. Joworowski, S. Lewin
Australia

11:20 **Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in gut associated lymphoid tissue (GALT): a randomized, placebo controlled trial**
C. Kovacs¹, J. Brunetta¹, T.-W. Chun², G. Smith¹, R. Halpenny¹, D. Su¹, O. Mario¹, G. Kandel¹, R. Kaul¹, J. Raboud¹, M. Loutfy¹
¹Canada, ²United States

11:30 **The effect of HIV-infection and highly-active anti-retroviral therapy on the human gut microbiome investigated by phylogenetic-targeted 454 pyrosequencing: a meta-genomic profile of duodenal biopsies, aspirates, and stool over time**
C.L. Ellis, C.-S. Li, S. Mann, Z.-M. Ma, H. Overman, A. Maniar, T. Yotter, E. Tsuchida, T.H. Knight, J.C. Rutledge, C.J. Miller, R.B. Pollard, D.M. Asmuth
United States

11:40 **Impact of tryptophan catabolism on CD4+ T cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy**
P. Hunt¹, S. Weiser¹, Y. Huang¹, C. Muzoora², A. Kembabazi², K. Ragland¹, J. Bennett¹, S. Deeks¹, D. Bangsberg¹, J. Martin¹, J. McCune¹
¹United States, ²Uganda

11:50 **Moderated discussion**

MOAC01 Structural Risks, Structural Interventions

Oral Abstract Session

Venue: Session Room 3

Time: Monday 18 July, 11:00-12:30

Co-Chairs: David Wilson, Zimbabwe
Giuliano Rizzardini, Italy

11:00 **Intimate partner physical and sexual violence are associated with perceived and actual HIV risk among hospital outpatients in rural Uganda**
S.M. Kiene^{1,2}, R. Wanyenze², M. Bateganya¹, H. Lule², H. Nantaba², M. Stein¹
¹United States, ²Uganda

11:15 **The role of HIV stigma and discrimination on the health and HIV-related protective behaviors of people living with HIV/AIDS in Rio de Janeiro, Brazil**
D. Kerrigan¹, M. Malta², N. Bertoni², F.I. Bastos², Rio Collaborative Group
¹United States, ²Brazil

11:30 **HIV/AIDS trend and major interventions in Iran prisons from 1999 to 2009**
M. Farnia, B. Ebrahimi, G. Moradi, M. Shahbazi
Iran, Islamic Republic of

11:45 **Linkage to care as a structural intervention: new HIV diagnoses in a community-based organization with integrated testing and HIV care services**
R. Bolan
United States

12:00 **A description of social capital in persons living with HIV/AIDS (PLWH)**
A. Weibel¹, J.C. Phillips², C. Dawson-Rose¹, I. Corless¹, J. Voss¹, L. Tyer-Viola¹, M. Rivero-Mendez¹, P. Nicholas¹, K. Nokes¹, J. Kempainen¹, E. Sefcik¹, J. Brion¹, L. Eller¹, K. Kirksey¹, D. Wantland¹, W. Holzemer¹, P. Chaiphibalsarisdi³, M. Johnson¹, C. Portillo¹, R. Salata¹, International HIV/AIDS Nursing Research Network
¹United States, ²Canada, ³Thailand

12:15 **Moderated discussion**

MOWS01 "Publish or Perish" Scientific Writing Workshop

Venue: Mini Room 1

Time: Monday 18 July, 11:00-14:00

Co-Facilitators: **Mirjam Eckert, Switzerland**
Shirin Heidari, Switzerland
Mark A. Wainberg, Canada
Susan Kippax, Australia
Papa Salif Sow, Senegal

Level: Foundation

Target Audience: Researchers, Clinicians, Novice, Technical

Seating Limit: 110

This interactive workshop provides an overview of the scientific writing process and an introduction to the publishing process for less experienced authors. The writing section will cover key components of a scientific manuscript and it will also highlight some of the resources available for authors. The publishing section will describe the publication and the peer-review process, and also address ethical issues in scientific writing. A panel of editors will give an insight into the workings of an editorial office and discuss the most common reasons for rejection of manuscripts. The aim is to make the editorial decision-making process transparent and provide practical information on how to navigate the publication process by avoiding common pitfalls. The workshop will be facilitated by the Journal of the International AIDS Society.

MOWS02 Improving Adherence and Quality of Care through Mobile Technology and Patient Education

Venue: **Mini Room 2**

Time: **Monday 18 July, 11:00-12:30**

Co-Facilitators: **Linda-Gail Bekker, South Africa**

Conall O'Cleirigh, United States

Level: Foundation, Intermediate, Advanced

Target Audience: Clinicians, Public Health Specialists, Programme Implementers, Policy Makers, Programme Managers, Researchers, Advocates

Seating Limit: 100

Adherence to treatment and programmes has proved to be an ongoing and growing challenge as treatment programmes in low- and middle-income countries (LMIC) expand and scale up. Programmes are finding innovative and novel ways to enhance both adherence to treatment as well as retention in care. These strategies often combine behavioural and technological methodologies. This workshop will review the literature on what is known about adherence and retention. A variety of behavioural, technological and other strategies will be presented. A number of case studies will be described and their efficacy and short falls discussed. These will be interactive sessions with opportunity throughout for audience participation and discussion. Finally there will be a panel discussion with a view to compiling recommended key components of an "adherence package" for LMIC in particular. Attendees who have new ideas that may not yet be published are encouraged to attend; there will be an opportunity to discuss new ideas.

MOSY01 Global Perspective on Migration and HIV/AIDS: Sharing Best Evidences and Practices in Policy and Research

Symposium

Venue: **Mini Room 4**

Time: **Monday 18 July, 11:00-12:30**

Co-Chairs: **Francesco Castelli, Italy**

Mario Bronfman, Mexico

The session will open with a general presentation on the global picture of the complex phenomenon of migration (epidemiology of migrations, including refugees, socio-economic determinants) and will include a comparison of available statistics, an analysis of the problems of compiling statistics, an overview of the ways that migrants become more vulnerable to contracting the virus, but also the positive aspects of migration that in some cases serve as prevention mechanisms (more information in destination country, better testing, etc.), and of course, stress the issue of vulnerability and rights. Subsequently, the session will focus on barriers to access to care (analyzing human rights as well as legal and economic aspects) and specific policies or programmes that have proved successful either in prevention or treatment of mobile populations by specific geographical areas of migration.

11:00 **Introduction**

11:05 **Migration: the global picture. Migrants as a vulnerable population**
R. Borland, Switzerland

11:25 **African migration to Europe**
E. M'Baye, France

11:40 **Migration to North America**
M. Negroni, United States

11:55 **Inter-regional migration in Asia**
M. Marin, Philippines

12:10 **Questions and answers**

12:25 **Conclusion**

Monday 18 July

13:00-14:00

MOSS01 Advancement of Science and Research on HIV

Special Session

Venue: **Session Room 1**

Time: Monday 18 July, 13:00-14:00

Co-Chairs: Hughes Fischer, France

Nikos Dedes, Greece [TBC]

The goal of this session is to review the evolution of the scientific challenges and accomplishments associated with HIV/AIDS throughout its 30-year history, while looking towards the future. Discussants will address major advancements and drawbacks in the research, and how specific scientific discoveries influenced policy, such as approaches towards treatment and prevention. Current and future challenges which remain to be explored will be discussed, such as HIV vaccines, HIV prevention, global access to HIV therapy and whether a functional cure of HIV is foreseen. The session will be highly engaging and interactive.

- 13:00 **Introduction**
- 13:05 **30 years of HIV/AIDS: a scientific journey and a look to the future**
A. Fauci, United States
- 13:30 **Discussing past and future accomplishments of HIV research**
F. Barré-Sinoussi, France
- 13:45 **Questions and answers**
- 13:55 **Conclusion**

MOPDD01 Human Resources: a Critical Factor for Success

Oral Poster Discussion

Venue: Session Room 3

Time: Monday 18 July, 13:00-14:00

Chair: Alexey Bobrik, Russian Federation

- 13:00 **Prevention of occupational exposures to blood-borne pathogens among HCW in Brazil: using surveillance data to guide the use of safety-engineered devices**
*C. Rapparini, V. Saraceni, G.C. Fernandes, A.A. Machado, PSBio Network - Surveillance System of Occupational Exposures to Blood-borne Pathogens among HCWs/Brazil
Brazil*
- 13:05 **Evaluation of a national program to improve injection safety in Tanzania**
*K. Kazaura, T. Pyun, E. Chenya, H. Ngonyani, I. Benech, D. Selenic
Tanzania, United Republic of*
- 13:10 **Innovative and efficient approaches for meeting the human resource needs of the male circumcision scale up in Southern and Eastern Africa**
*K. Curran¹, A. Mirelman¹, E. Njeuhmeli¹, K. Dickson², T. Adamu¹, P. Cherutich³, T.K. Mavuso⁴, J. Albertini⁴, L. Fitzgerald⁴, N. Bock⁵, J. Reed¹, D. Stanton¹
¹United States, ²Switzerland, ³Kenya, ⁴Swaziland, ⁵Georgia*
- 13:15 **Task-shifting of HIV care and ART initiation: three year evaluation of a mixed-care provider model for ART delivery**
*M. McGuire¹, G. Pedrono², S. Goossens³, A. Heinzlmann³, O. Chikwaza², E. Szumilin³, M. Berthelot³, M. Pujades-Rodriguez³
¹Kenya, ²Malawi, ³France*
- 13:20 **The effect of task-shifting antiretroviral care in South Africa: a pragmatic cluster randomised trial (STRETCH – streamlining tasks and roles to expand treatment and care for HIV)**
*L. Fairall¹, M. Bachmann², C. Lombard¹, V. Timmerman¹, K. Uebel¹, M. Zwarenstein^{1,3}, A. Boulle¹, D. Georgeu¹, C. Colvin¹, S. Lewin^{1,4}, G. Faris¹, R. Cornick¹, M. Tshabalala¹, E. Kotze¹, C. van Vuuren¹, D. Steyn¹, E. Bateman¹
¹South Africa, ²United Kingdom, ³Canada, ⁴Norway*
- 13:25 **Moderated discussion**

MOPDC01 Reaching the Hard to Reach with Testing

Oral Poster Discussion

Venue: Mini Room 3

Time: Monday 18 July, 13:00-14:00

Co-Chairs: Peter Cherutich, Kenya

Heidi van Rooyen, South Africa

- 13:00 **Introduction**
- 13:05 **A switch to opt-out HIV testing and counseling triples testing uptake among MC clients in Gambella, Ethiopia**
*Y. Abduljewad¹, A. Shume¹, K. Curran², E. Daniel¹, S. Mengistu¹, T. Adamu²
¹Ethiopia, ²United States*
- 13:10 **Reaching out to men in Soweto through a community-based VCT approach**
*G. Robertson, S. Mhlongo, M. Van der Watt, G. Gray
South Africa*
- 13:15 **Effectiveness of a pilot voucher-based referral system to enhance uptake of HIV testing by high risk clients in Northern Tanzania**
*E. Reddy^{1,2}, R. Waters¹, B. Njau², A. Mtal², P. Dominic², D. Itemba², J. Ostermann¹, N. Thielman¹
¹United States, ²Tanzania, United Republic of*
- 13:20 **Determinants of voluntary HIV counseling and testing (VCT) among female sex workers (FSW) in Nigeria**
*B. Ogunbiyi, B. Aiyenigba, T. Badru, C. Suzuki, C. Hamelmann, O. Chabikuli
Nigeria*

- 13:25 **A systematic review of HIV self-testing: research, policy and a new era in HIV prevention**
S. Napierala Mavedzenge, E.L. Corbett
United Kingdom
- 13:30 **Study on effect of provider initiated HIV testing and consulting (PITC) at areas inhabited by ethnic minorities with high HIV epidemic**
L. Chongxing, G. Yuhan, L. Peng, L. Hui, L. Zhongfu, H. Yuchuan, H. Malonne
China
- 13:35 **Moderated discussion**

MOPDD02 HIV Testing: Innovation and Scale-Up

Oral Poster Discussion

Venue: Mini Room 4

Time: Monday 18 July, 13:00-14:00

Co-Chairs: Didier Koumavi Ekouevi, Cote D'Ivoire
Willy Rozenbaum, France

- 13:00 **Toward universal HIV testing: is the Centers for Disease Control and Prevention (CDC) recommendation of "opt-out" screening the answer?**
A. Mahajan, J. Sayles, J. Kinsler, S. James, J. Rurangirwa, R. Manchanda, L. Makam, T. Coates, M. Shapiro
United States
- 13:05 **Increasing rates of HIV testing and HIV knowledge in Durban, South Africa: time trends over four years**
L. Bassett¹, S. Regan¹, S. Chetty², J. Giddy², D. Ross², J. Katz¹, K. Freedberg¹, E. Losina¹, R. Walensky¹
¹United States, ²South Africa
- 13:10 **Expanding access to HIV counseling and testing to all family members through home based testing and counseling (HBTC) in Suba district, Kenya**
U. Benson Otieno, M. Grace, K. Charles, A. Steve, M. Winfred, A. Gichangi
Kenya
- 13:15 **HIV testing and diagnosis of emergency department patients in New Jersey, 2005 – 2008**
C. Sadashige, S. Paul, E. Martin
United States
- 13:20 **Evaluating the impact of adding HIV counseling and testing to the basic package of health services - a study of health extension workers in Ethiopia**
M. Nowakowski¹, F. Walsh¹, A. Zerihun², H. Tezera², H. Seyoum², L. Ahmed², Y. Abebe²
¹United States, ²Ethiopia
- 13:25 **Challenges of early infant HIV diagnosis and treatment in Malawi**
O. Dube¹, A. Dow², J. Lebov², C. Chirambo¹, M. Moore¹, R. Heyderman¹, A. Van Rie²
¹Malawi, ²United States
- 13:30 **Moderated discussion**

Monday 18 July
14:25-16:00

MOBS01 HIV and Co-Infections: HCV, Malaria, TB and Beyond

Bridging Session

Venue: Session Room 1

Time: Monday 18 July, 14:25-16:00

Co-Chairs: Papa Salif Sow, Senegal
Paula Munderi, Uganda

Aimed at physicians, microbiologists and epidemiologists who are interested in the care and treatment of persons living with HIV, this session will highlight the interactions between HIV and TB, malaria, hepatitis and HSV. The session will thus describe the interactions between HIV and TB drugs, the integration of the two programmes and drug resistance issues. Subsequently, it will focus on malaria as a factor influencing the clinical progression of HIV disease and the role of malaria during pregnancy in HIV positive women. The session will also highlight the co-infection management strategies between TB and hepatitis viruses.

- 14:25 **Award Presentation: IAS TB/HIV Research Prize**
- 14:30 **Introduction**
- 14:35 **HIV and TB**
A. Matteelli, Italy
- 14:45 **HIV and malaria**
J. Achan, Uganda
- 14:55 **HIV and HCV**
V. Soriano, Spain

- 15:05 **HIV and other co-infections (HSV)**
C. Celum, United States
- 15:15 **Questions and answers**
- 15:55 **Conclusion**

Monday 18 July
14:30-16:00

MOAC02 Biologic Insights: Interventions for HIV Transmission

Oral Abstract Session

Venue: Session Room 2

Time: Monday 18 July, 14:30-16:00

Co-Chairs: Elizabeth Bukusi, Kenya
Gabriella Scarlatti, Italy

- 14:30 **Valacyclovir suppression reduces breast milk and plasma HIV-1 RNA postpartum: results of a randomized clinical trial**
A. Drake¹, A. Roxby¹, F. Ongecha-Owuor², J. Kiarie², A. Wald¹, G. John-Stewart¹, B. Richardson¹, J. Overbaugh¹, S. Emery¹, C. Farquhar¹
¹United States, ²Kenya
- 14:40 **Association of bacterial vaginosis with female-to-male HIV-1 transmission among HIV-1 discordant couples in Sub-Saharan Africa**
C.R. Cohen¹, J.R. Lingappa¹, J.M. Baeten¹, M.O. Ngayo², C.A. Spiegel¹, T. Hong¹, D. Donnell¹, C. Celum¹, S. Kapiga¹, S. Delany³, E.A. Bukusi², Partners in Prevention HSV/HIV Transmission Study Team
¹United States, ²Kenya, ³South Africa
- 14:50 **Susceptibility to transmit HIV in ART-treated individuals: longitudinal analysis from Stratal ANRS 12110/ESTHER trial**
J. Cohen¹, S. Boyer¹, C. Kouanfack², M.P. Carrieri¹, G. Ndziessi¹, C. Protopopescu¹, J.-P. Moatti¹, E. Delaporte¹, C. Laurent¹, B. Spire¹, Stratal ANRS 12110/ESTHER Study Group
¹France, ²Cameroon
- 15:00 **Genital secretions of HIV-1 infected women on effective antiretroviral therapy contain high drug concentrations and low amounts of cell-free virus**
A. Sheth¹, T. Evans-Strickfaden¹, A. Martin¹, C. Gatcliffe¹, A. Adesoye¹, M. Omondi¹, R. Haaland¹, L.D. Lupo¹, K. Easley¹, C.-P. Pau¹, C. Hart¹, I. Ofotokun¹
United States
- 15:10 **Phylogenetic insight into HIV transmission networks in a Southeastern US cohort**
A.M. Dennis¹, S. Hué², C.B. Hurt¹, S. Napravnik¹, D. Pillay², J.J. Eron¹
¹United States, ²United Kingdom
- 15:20 **Impact of the national prevention of mother to child transmission (PMTCT) program on mother-to-child transmission of HIV (MTCT), South Africa, 2010**
A. Goga¹, T.-H. Dinh², N. Dlamini¹, T. Mosala¹, C. Lombard¹, A. Puren¹, G. Sherman¹, S. Crowley¹, S. Woldesenbet¹, W. Solomon¹, N. Kula¹, V. Ramokolo¹, Y. Pillay¹, D. Jackson¹, South Africa PMTCT Effectiveness Survey (SAPMTCTE) team
¹South Africa, ²United States
- 15:30 **Moderated discussion**

MOAC03 Novel Approaches to Prevention Interventions and Measurement

Oral Abstract Session

Venue: Session Room 3

Time: Monday 18 July, 14:30-16:00

Co-Chairs: Giuseppe Ippolito, Italy
Moupali Das, United States

- 14:30 **Vaginal ring adherence in Sub-Saharan Africa: expulsion, removal and perfect use**
E. Montgomery¹, A. van der Straten¹, H. Cheng¹, L. Wenger¹, G. Masenga², H. Rees³, L. Gail-Bekker³, S. Ganesh³, K. Young³, J. Romano¹, A. Nel³, C. Woodson³
¹United States, ²Tanzania, ³United Republic of, ³South Africa
- 14:45 **Acceptability of potential rectal microbicide delivery mechanisms for HIV prevention**
H. Pines¹, P. Gorbach¹, R. Weiss¹, K. Hess¹, R. Murphy¹, T. Saunders¹, L. Colemon¹, E. Robbie¹, J. Brown¹, R. Cranston¹, P. Anton¹
United States
- 15:00 **Cumulative plasma HIV-1 level as a novel tool to evaluate antiretroviral therapy efficacy at the individual and public health levels**
V.D. Lima¹, J. Sierra-Madero², Z. Wu³, J. Singer¹, D. Milan¹, J. Montaner¹
¹Canada, ²Mexico, ³China
- 15:15 **Mobile phone-based data collection to enhance retention of racial/ethnic minorities in a longitudinal internet-based HIV behavioral risk study of MSM in the United States**
C. Khosropour¹, P. Sullivan¹
United States
- 15:30 **Audio computer assisted self interview (ACASI) versus face-to-face interview methods in reporting HIV risk behaviors among men who have sex with men (MSM) in Nigeria**

15:45 **Moderated discussion**

MOWS03 Pathogenesis and Management of Long-Term Complications of ART

Venue: Mini Room 1

Time: Monday 18 July, 14:30-16:00

Co-Facilitators: Steven Deeks, United States
Cissy Kityo Mutuluza, Uganda

Level: Advanced

Target Audience: Basic and Translational Scientists, Health Care Providers, Policy Specialists

Seating Limit: 100

The workshop is aimed at broadening participants understanding of the basic mechanisms underlying the long-term complications of ART, including both those directly induced by drugs and those related to the incomplete suppression of viremia and/or incomplete immune reconstitution. The workshop will focus on the decision-making process in the diagnosis and treatment of long-term complications of ART and the ability to manage the long-term adverse effects of commonly used anti-retroviral drugs. Furthermore, participants will explore the prognosis of antiretroviral-treated adults as compared to age-matched uninfected adults. Four presentations will be given with time for questions and answers. The presentations will address the epidemiology of non-AIDS morbidity and mortality, the role of treatment toxicity, inflammation/immune dysfunction and traditional risk factors associated with cardiovascular and other diseases, and recommendations on how to screen for such diseases in a primary care setting. Issues pertaining to both resource-rich and resource-limited regions will be covered.

MOWS04 Sex Work and the Risk Environment: Beyond the Individual. Structural Approaches to HIV Prevention among Sex Workers

Venue: Mini Room 2

Time: Monday 18 July, 14:30-16:00

Co-Facilitators: Deanna Kerrigan, United States
Steffanie Strathdee, United States

Level: Intermediate

Target Audience: Researchers, Programme Development and Implementation Staff

Seating Limit: 50

This workshop will focus on skills that address the conceptualization, measurement, development and evaluation of environmental-structural approaches to HIV prevention in the context of sex work. The workshop will include presentations and discussions on field experience and intervention research from the Dominican Republic, Brazil and Mexico. Participants will discuss the concept of environmental-structural interventions in the context of sex work; gain knowledge of measurement and evaluation designs appropriate for these interventions; and learn successful strategies for addressing the environment surrounding sex work and HIV prevention in distinct settings.

Monday 18 July
16:30-18:00

MOSY02 Current Challenges in HIV Disease Management

Symposium

Venue: Session Room 1

Time: Monday 18 July, 16:30-18:00

Co-Chairs: Beatriz Grinsztejn, Brazil
Anton Pozniak, United Kingdom

Although, in developed countries, survival is not an issue anymore, there are still treated patients who seem to be more fragile than the uninfected population. This session will thus address the current challenges in managing this group of patients. It will first focus on late presenters in both developed and developing countries where there is still a large number of late diagnoses and provide the latest data in how best to manage these patients. In a context of long life expectancy, the session will also address what it means getting old with HIV infection and with a continuous inflammation. Subsequently, it will analyse patients with long term controlled viremia who are not completely recovered because residual viral replication in reservoirs maintain a status characterized by several immunological abnormalities. Finally, the session will focus on the long term management of patients with long term suppressed viremia.

16:30 **Introduction**

16:35 **Treatment of patients late presenters**
P. Cahn, Argentina

16:50 **Aging with HIV infection**
W. Powderly, Ireland

17:05 **Immuno-virological discordance in treated suppressed patients**
J. Blanco, Spain

17:20 **Emerging co-morbidities in the setting of long-term virologic suppression**
A. Castagna, Italy

17:35 **Questions and answers**

17:55 **Conclusion**

MOAX01 Treatment as Prevention: Results from HPTN 052**Oral Abstract Session****Venue:** Session Room 2**Time:** Monday 18 July, 16:30-18:0016:30 **Introduction**16:35 **Antiretroviral treatment to prevent the sexual transmission of HIV-1: results from the HPTN 052 multinational randomized controlled trial**

M. Cohen¹, Y. Chen¹, M. McCauley¹, T. Gamble¹, R. Bollinger¹, Y. Bryson¹, D. Burns¹, D. Celentano¹, S. Chariyalertsak², L. Cottle¹, G. De Bruyn³, V. Elharrar¹, S. Eshleman¹, M. Essex¹, E.C.J. Filho⁴, S. Godbole⁵, B. Grinsztejn⁴, J.G. Hakim⁶, I.F. Hoffman¹, M. Hosseinipour¹, J. Kumwenda⁷, J. Makhema⁸, A. Martinez¹, K.H. Mayer¹, S. Mehendale⁵, L.A. Mills¹, K.A.-H. Nielsen¹, J.H.d.S. Pilotto⁴, E. Piwowar-Manning¹, I. Sanne³, B.R. Santos⁴, T. Taha¹, L. Wang¹, T. Fleming¹, S. Saffren¹, HPTN052 Protocol Team
¹United States, ²Thailand, ³South Africa, ⁴Brazil, ⁵India, ⁶Zimbabwe, ⁷Malawi, ⁸Botswana

16:45 **Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network (HPTN) 052 trial**

J. Hughes¹, S. Hudelson¹, A. Redd¹, L. Wang¹, R. Debes¹, Y. Chen¹, S. Porcella¹, E. Piwowar-Manning¹, M. McCauley¹, M. Hosseinipour^{1,2}, J. Kumwenda², J. Hakim³, S. Chariyalertsak⁴, G. de Bruyn⁵, B. Grinsztejn⁶, N. Kumarasamy⁷, J. Makhema⁸, K. Mayer¹, J. Pilotto⁶, B. Santos⁶, T. Quinn¹, M. Cohen¹, S. Eshleman¹, HPTN 052
¹United States, ²Malawi, ³Zimbabwe, ⁴Thailand, ⁵South Africa, ⁶Brazil, ⁷India, ⁸Botswana

16:55 **Immunologic and virologic disease progression and responses to ART across geographic regions: outcomes from HPTN 052 study**

M.C. Hosseinipour^{1,2}, L. Wang², M.S. Cohen², S. Chariyalertsak³, Y.Q. Chen², V. Elharrar², S. Eshleman², J. Gallant², T. Gamble², S. Godbole², S. Govinder², B. Grinsztejn⁶, J.G. Hakim⁷, D. Havlir², P. Ive⁵, K. Klingman², N. Kumarasamy⁴, J. Kumwenda¹, J. Makhema⁸, K. Mayer², M. McCauley², L. Mills², J. Pilotto⁶, E. Piwowar-Manning², H. Ribaudo², B.R. Santos⁶, S. Swindells², J.J. Eron², and the HPTN 052 study team
¹Malawi, ²United States, ³Thailand, ⁴India, ⁵South Africa, ⁶Brazil, ⁷Zimbabwe, ⁸Botswana

17:05 **Effects of early versus delayed initiation of antiretroviral therapy (ART) on HIV clinical outcomes: results from the HPTN 052 randomized clinical trial**

B. Grinsztejn¹, H. Ribaudo², M.S. Cohen², S. Swindells², S. Badel-Faesens³, D. Burns², S. Chariyalertsak⁴, Y.Q. Chen², G. De Bruyn³, J.J. Eron², S. Eshleman², T. Fleming², J. Gallant², T. Gamble², S.V. Godbole⁵, J.G. Hakim⁶, M.C. Hosseinipour^{2,7}, K. Klingman², N. Kumarasamy⁵, J. Kumwenda⁷, J. Makhema⁸, K.H. Mayer², M. McCauley², L.A. Mills², J.H. Pilotto¹, E. Piwowar-Manning², B.R. Santos¹, L. Wang², D. Havlir², HPTN 052 Protocol Team
¹Brazil, ²United States, ³South Africa, ⁴Thailand, ⁵India, ⁶Zimbabwe, ⁷Malawi, ⁸Botswana

17:15 **Summary and conclusion**17:30 **Questions and answers**

MOAD01 Diagnostics: Innovation, Cost-Effectiveness and Scale-Up**Oral Abstract Session****Venue:** Session Room 3**Time:** Monday 18 July, 16:30-18:00**Co-Chairs:** Christine Rouzioux, France

Guido Antonelli, Italy

16:30 **Cost comparison of point-of-care and laboratory CD4 testing in resource-limited settings**

L. Jani, N. Sitoe, J. Quevedo, J. Lehe, T. Peter
Mozambique

16:40 **Cost-effectiveness of Xpert MTB/RIF for screening for tuberculosis prior to antiretroviral therapy in South Africa**

J.R. Andrews¹, S.D. Lawn^{2,3}, C. Rusu¹, R. Wood², E. Rhode¹, M.A. Bender¹, C.R. Horsburgh¹, F. Noubary¹, K.A. Freedberg¹, R.P. Walensky¹
¹United States, ²South Africa, ³United Kingdom

16:50 **Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa**

B. Larson¹, K. Bistline², B. Ndibongo², T. Xulu², A. Brennan¹, L. Long², S. Rosen¹, M. Fox¹
¹United States, ²South Africa

17:00 **The cost-effectiveness of on-site rapid HIV testing in substance abuse treatment: results of the CTN 0032 randomized trial**

B.R. Schackman, L.R. Metsch, G.N. Colfax, J.A. Leff, A.Y. Wong, C.A. Scott, D.J. Feaster, L. Gooden, T. Matheson, R.N. Mandler, L.F. Haynes, A.D. Paltiel, R.P. Walensky
United States

17:10 **Point-of-care CD4 tests can increase life-years saved with reduced costs compared to flow cytometric CD4 counting**

C.L. Grundy¹, A. Medina Lara², D. Winogron¹, A.P. Croucher¹, H.-G. Batz¹, T.B. Hallett¹, S.D. Reid¹
¹United Kingdom, ²Italy

17:20 **Moderated discussion**

MOSY04 1981-2011: Thirty Years Later, What We Know and Don't Know on How HIV Causes AIDS**Symposium****Venue:** Mini Room 4**Time:** Monday 18 July, 16:30-18:00**Co-Chairs:** Guido Silvestri, United States

Leonid Margolis, United States

The goal of this session is to summarize the most recent advances on the immunopathogenesis of AIDS. This is a highly significant topic with enormous ramifications in terms of HIV prevention and therapy. The session will include four talks: a historical perspective, a talk on natural SIV infections, a talk on the causes of immune activation, and a talk on immune-based interventions. Hopefully, the audience will leave the room with a clear perspective of what we know and what we still need to know about AIDS pathogenesis, and how this knowledge impacts the clinical management of HIV-infected individuals.

- 16:30 **Introductory remarks**
- 16:35 **Immunopathogenesis of AIDS: a historical perspective**
M. Lederman, United States
- 16:50 **Viral determinants of AIDS Pathogenesis**
F. Kirchhoff, Germany
- 17:05 **Learning from nature: non-pathogenic SIV infection of African monkeys**
M. Müller-Trutwin, France
- 17:20 **Immune-based interventions for HIV infection and AIDS**
A. Landay, United States
- 17:35 **Discussion**
- 17:55 **Closing remarks**

Monday 18 July
18:30-20:00

MOSA01 Changing Perspectives: Long-Term Treatment Success **Commercial Satellite**

Venue: Session Room 2

Time: Monday 18 July, 18:30-20:00

Until recently, HIV treatment has focused on short-term goals, such as rapid reduction in viral load and immune restoration; however, advances in the management of HIV have resulted in a shift towards understanding longer-term outcomes. The availability of modern HAART, which demonstrates durable suppression, favourable safety and tolerability profiles and convenient dosing, allow us to turn our attention to optimising treatment for long-term success.

This educational meeting, aimed at HIV-treating physicians, will consist of a mixture of interactive plenary and panel discussion sessions exploring topics such as measures of long-term treatment success and the concepts of genetic barrier and forgiveness. The international expert faculty will also present key clinical data around current and emerging treatment strategies and uncover the challenges to long-term success in treating HIV-positive patients.

- 18:30 **Opening session Changing perspectives: Defining long-term treatment success**
- 18:45 **Setting the scene: Current guidelines and beyond**
- 19:10 **Putting potency and genetic barrier into perspective**
- 19:35 **Challenges to long-term success in HIV treatment**

MOSA02 Controversies in HIV Cure Research **Non-Commercial Satellite**

Venue: Session Room 3

Time: Monday 18 July, 18:30-20:30

While it is known that antiretroviral therapy does not cure HIV infection, several controversies in the field of HIV cure research remain unresolved and have the potential to redirect lines of scientific inquiry including strategies aimed at curing HIV infection. In this session, basic and clinical research experts will present evidence for each side of the debates around three controversies drawn from basic, preclinical and clinical research. A moderator for each debate will pose questions to each speaker and field questions from the audience.

- 18:30 **Is there ongoing replication under HAART?**
- 19:10 **Will cell and animal models be informative in planning clinical trials for a cure (or will we only learn from doing the trials)?**
- 19:50 **Are we most likely to cure HIV with gene therapy?**

MOSA03 Respect-Protect-Sustain – Developing Guidelines for MSM/HIV-related Researchers and Community-based Organizations **Non-Commercial Satellite**

Venue: Mini Room 1

Time: Monday 18 July, 18:30-20:30

This roundtable discussion will elicit feedback on draft guidelines being developed for both HIV-related researchers and community-based organizations to ensure effective research amongst gay and bisexual men, other MSM and transgender individuals. Recognizing the inherent challenges faced by these marginalized populations, especially in the Global South, the guidance suggests practical ways in which all concerned

partners can increase the impact and reach of such research, as well as reduce the potential risks and harms these marginalized individuals may encounter. The draft guidance proposes a research approach that increases the capacity of researchers to meet their research obligations, and at the same time, encourages gay and bisexual men, other MSM, and transgender individuals and organizations to exercise their rights when participating in research projects. Finally, example engagement rules for studies and projects which encounter or engender threatening media, political, or social/ religious backlash are offered.

MOSA04 The Decade of Diagnostics: Opportunities and Challenges to bring Innovation to the Developing World

Non-Commercial Satellite

Venue: Mini Room 2

Time: Monday 18 July, 18:30-20:30

Diagnostics are the gateway to care and treatment for HIV/AIDS, and yet access to testing for people living with HIV/AIDS in resource-poor settings is often limited at best. Testing for HIV/AIDS requires a continuum of tests beginning with initial detection of the disease, followed by CD4 testing (for staging and monitoring the disease prior to treatment initiation) and viral load testing (for monitoring of antiretroviral therapy post-initiation). Although HIV rapid testing has made initial disease detection inexpensive and accessible, CD4 and viral load testing remain centralized, requiring dedicated laboratory space, sophisticated infrastructure and trained technicians. Such testing is often costly and simply inaccessible, especially for those in rural settings. But, change is coming in the form of unprecedented activity in the development of promising new CD4 and viral load technologies designed to be used at or near the patient point of care. The next ten years may will prove to be the "decade of diagnost

MOSA05 Pre-Exposure Prophylaxis (PrEP): How Will the Future Pipeline Look Like?

Non-Commercial Satellite

Venue: Mini Room 3

Time: Monday 18 July, 18:30-20:30

Given the exciting results of CAPRISA and iPREX, this satellite session will present what is currently in the research pipeline as far as ARV-based prevention products and what future products may look like.

MOSA06 Treatment 2.0: Meeting the Challenges of the Next Phase of HIV Treatment

Non-Commercial Satellite

Venue: Mini Room 4

Time: Monday 18 July, 18:30-20:30

The Treatment 2.0 Initiative was launched at the IAC 2010 in Vienna. Since that time, there has been both great interest in the components and implementation strategy of the Initiative. The purpose of the Satellite Session is to provide further information to IAC attendees about Treatment 2.0, report on the activities undertaken since Vienna, and present the work plan for the coming year. This Satellite will be co-sponsored by UNAIDS and WHO with support from the Bill and Melinda Gates Foundation. Invited speakers include Michel Sidibe, Eric Goosby, Julio Montaner.

Tuesday 19 July
07:00-08:30

TUSA01 Building Global HIV/AIDS Clinical Pharmacology Research Capacity

Non-Commercial Satellite

Venue: Mini Room 1

Time: Tuesday 19 July, 07:00-08:30

Building Global HIV/AIDS Clinical Pharmacology Research Capacity includes areas such as: Mobilizing Resources to Address Global Clinical Pharmacology Capacity Needs, Capacity Challenges to the use of Current HIV and TB and Developing Research Strategies for New Drugs, HIV and Traditional Medicine Use in Africa, Drug Interactions and Pharmacogenomics Research, Quality Assurance Planning for HIV Clinical Pharmacology Capacity Building and Establishing Regional Centers of Excellence. These topics will be discussed and audience questions and answers will accompany a final panel discussion.

TUSA02 Optimizing HIV Treatment – A Global Strategy in Three Acts

Non-Commercial Satellite

Venue: Mini Room 2

Time: Tuesday 19 July, 07:00-08:30

Optimized HIV treatment is the cornerstone of ensuring that people living with HIV/AIDS achieve sustained viral suppression. In light of health workforce constraints and antiretroviral therapy gaps, achieving this universal goal requires addressing three important challenges: 1) the need to implement a strategic framework to harmonize global efforts to optimize HIV treatment; 2) the need to integrate into clinical practice evidence-based behavioral, clinical, and structural interventions to improve retention in and adherence to HIV treatment; and 3) the need to improve the efficiency and effectiveness of the existing health workforce through the use of multidisciplinary care teams (MCT). This satellite meeting will examine how the "Treatment 2.0" strategy can catalyze treatment optimization efforts, and how retention in care/adherence and MCT interventions can facilitate increased treatment access and improved treatment outcomes for people living with HIV/AIDS worldwide.

07:00 **Treatment 2.0 – Catalyzing the Next Phase of HIV Treatment, Care, and Support**

07:20 **Developing Guidelines to Promote Treatment Adherence, Entry Into, and Retention in Care**

07:40 **Treatment Optimization via Multidisciplinary Care Team Delivery of Integrated HIV Services**

08:00 **Optimized Multidisciplinary Care Teams Enhance Antiretroviral Therapy Adherence**

08:20 **Question & Answer Session**

TUSA03 NAPWAs' Treatment Horizons: Pathways to a Functional Cure**Non-Commercial Satellite****Venue: Mini Room 3****Time: Tuesday 19 July, 07:00-08:30**

Resistance to current treatments is reaching a critical mass. People living with HIV/AIDS desperately need a new generation of treatments before resistance makes the current class of anti-retroviral drugs obsolete. New treatments are needed to address the different needs of PLWHAs in developing countries, rural, and underserved communities at higher risk for drug resistance. We can save lives if an emerging, new broad range of therapeutic interventions for HIV/AIDS and co-morbidities are rapidly accelerated.

Accordingly, in 2010, NAPWA launched the HIV BOOST Initiative to expedite the development of new medicines to save the lives of the most vulnerable and diverse patient populations. This symposium is designed to educate researchers, advocates, and people with HIV and AIDS about immune-based therapy research that one day may lead to a breakthrough for people living with the virus. NAPWA will present a series of brief presentations from developers of a broad range of investigational therapeutic interventions for HIV/AIDS and co-morbidities.

Some of this research aims to develop a therapeutic vaccine that could give uninfected people lasting if not permanent protection against infection, resulting in a prophylactic vaccine. A successful therapeutic vaccine would offer significant benefits:

- Significantly reduced risk of drug toxicities for people living with HIV
- Potential for eliminating HIV in reservoirs and sanctuary regions
- Preservation of immune system function and stimulation of HIV-specific immunity
- Minimal administration and less dependence on taking pills every day - only a few injections and boosters would be necessary to improve patient immune system function
- Dramatically lower costs than current HAART drugs
- Progress towards a possible *permanent* "functional cure" for HIV/AIDS

Prominent researchers have not given up looking for a functional cure. In a recent brilliant editorial in *The New York Times*, Nobel laureate and President-elect of the International AIDS Society Françoise Barré-Sinoussi writes:

I believe that given our current knowledge and innovative tools and concepts, a functional cure is a more realistic goal for the near future.

Founded in 1983 as the first and largest advocacy group for people living with HIV/AIDS, NAPWA is the trusted independent voice for all people living with the virus in the United States. NAPWA remains a strong voice in policy, capacity building, leadership development, and social networking. NAPWA is a 501(c) 3 non-profit organization based in Silver Spring, Maryland. For more information about NAPWA, please visit www.napwa.org.

TUSA04 Zeroing out New Infections through Prevention Tools and Technologies**Non-Commercial Satellite****Venue: Mini Room 4****Time: Tuesday 19 July, 07:00-08:30**

This satellite session will explore innovative tools and technologies which may be used to achieve zero new HIV infections towards halting and reversing the spread of HIV/AIDS by 2015. We will explore the benefits, challenges, and opportunities of prevention research; prospects in microbicides to reach zero new infections; how women's centered approaches can be used as a prevention tool; and finally cost-effectiveness of treatment as prevention.

Potential Speakers include:

Jeffrey Sturchio, President and CEO, Global Health Council

Michel Sidibe, Executive Director, Joint United Nations Programme on HIV/AIDS

Mitchell Warren, Executive Director, AVAC

Chirfi Guindo, VP and Managing Director, Merck

Zeda Rosenberg, Chief Executive Officer, International Partnership for Microbicides

Carole Presern, Director of The Partnership for Maternal, Newborn & Child Health (PMNCH)

Tuesday 19 July**08:55-10:30**

TUPL01 Tuesday Plenary Session**Plenary****Venue: Session Room 1****Time: Tuesday 19 July, 08:55-10:30****Co-Chairs: Cheryl Smith, United States****Joep Lange, Netherlands****Jean-François Delfraissy, France****08:55 Award Presentation: IAS/ANRS Young Investigator Award****09:00 The Social Barriers to Effective HIV Prevention***S. Kippax, Australia***09:25 Challenges in HIV Treatment and Care in a Resource Constrained Environment***S. Eholié, Cote D'Ivoire***09:50 The AIDS Response: The Need for a Long Term View***P. Piot, Belgium*

Tuesday 19 July
11:00-12:30

TUAB01 New Drugs and Strategies
Oral Abstract Session

Venue: Session Room 1

Time: Tuesday 19 July, 11:00-12:30

Co-Chairs: David Back, United Kingdom
Zhang Fugie, China

- 11:00 **Efficacy and safety of lersivirine (UK-453,061) vs. efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicentre, randomised, double-blind, phase IIb trial (study AS271015)**
P. Vernazza¹, C. Wang², A. Pozniak², E. Weil², P. Pulik³, D. Cooper⁴, R. Kaplan⁵, A. Lazzarin⁶, H. Valdez², J. Goodrich², M. Tawadrous²
¹Switzerland, ²United States, ³Poland, ⁴Australia, ⁵South Africa, ⁶Italy
- 11:10 **Rapid, robust and sustained antiviral response with once-daily (QD) dolutegravir (DTG, S/GSK1349572), a next generation integrase inhibitor (INI) in combination therapy in antiretroviral-naïve adults: 48 week results from SPRING-1 (ING112276)**
J. van Lunzen¹, F. Maggiolo², B. Phung³, O. Tsybakova⁴, B. Young^{5,6}, J. Gatell⁷, S. Almond⁸, M. St Clair⁵, C. Brothers⁵, S. Min⁵
¹Germany, ²Italy, ³France, ⁴Russian Federation, ⁵United States, ⁶Netherlands, ⁷Spain, ⁸Canada
- 11:20 **48-week results of a dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) + ATV/r in treatment-naïve (TN) patients infected with CCR5-tropic HIV-1**
S. Portsmouth¹, C. Craig², A. Mills¹, D. Mildvan¹, D. Podzamczek³, G. Fätkenheuer⁴, M. Lea³, H. Valdez¹, S.R. Valluri¹, J. Heera¹
¹United States, ²United Kingdom, ³Spain, ⁴Germany
- 11:30 **Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo-controlled trial in Rakai, Uganda**
S. Reynolds¹, F. Makumbi², N. Kiwanuka², K. Newell¹, P. Ssebowa², V. Sempijija², F. Bbosa², R. Gray¹, M. Wawer¹, T. Quinn¹, D. Serwadda²
¹United States, ²Uganda
- 11:40 **HIV-1 viremia persists despite autologous bone marrow transplantation for AIDS-related lymphoma**
A. Cillo, A. Krishnan, D. McMahon, S. Li, J. Rossi, J. Zaia, J. Mellors
United States
- 11:50 **Moderated discussion**

TUSY01 Preventive and Therapeutic HIV Vaccines: Novel Candidates and Strategies in 2011
Symposium

Venue: Session Room 2

Time: Tuesday 19 July, 11:00-12:30

Co-Chairs: Barbara Ensoli, Italy
Yiming Shao, China

The session is designed to provide a general introduction for those not in the field, with an updated overview on the status of HIV vaccines in terms of outcome of recent preventive and therapeutic trials as well as new concepts being developed and tested, including clinical trial design, new vaccine candidates and delivery systems. Therapeutic vaccination as an approach to intensify, simplify or interrupt HAART therapy, as well as to contribute to HIV eradication will be discussed. Results from recent selected preventative and therapeutic approaches, which appear particularly stimulating and promising, will be presented. The session is designed to favour the interaction and discussion on the different strategies, including a comparison of the rationale behind the preventive and therapeutic approaches and what they can learn from each other to advance the field.

- 11:00 **Introduction**
- 11:05 **Preventative and therapeutic HIV vaccines: where we stand now and what we foresee**
B. Ensoli, Italy
- 11:15 **Env-based vaccines**
S. Zolla-Pazner, United States
- 11:30 **Antibody-mediated vaccines protection against HIV: the critical path to next phase of proof of concept HIV vaccine trials**
S. Barnett, United States
- 11:45 **DNA vaccines**
D. Weiner, United States
- 12:00 **Dendritic cell-based therapeutic vaccine approaches**
F. Garcia, Spain
- 12:15 **Questions and answers**
- 12:25 **Conclusion**
-

TUSY02 Where Are Harm Reduction Programmes for Injecting Drug Users Going?**Symposium****Venue: Session Room 3****Time: Tuesday 19 July, 11:00-12:30****Co-Chairs: Jacques Normand, United States
Kora DeBeck, Canada**

It has been 25 years since the first needle exchange and harm reduction programmes for people who inject drugs were first introduced. These programmes have consistently demonstrated their effectiveness in reducing the number of new HIV infections among Injecting Drug Users (IDUs) as well as increasing their quality of life. Yet there are still political and moral barriers to implementing such programmes on a larger scale. Only 8% of IDUs receive Opioid Substitution Therapy and only 4% are treated for HIV. Is the effectiveness of such programmes still questionable by some? Could the achievements of harm reduction programmes be at stake due to political reluctance? This session will show examples of successful harm reduction programmes and discuss the way to go forward.

- 11:00 **Introduction**
J. Normand, United States
- 11:05 **Presentation of speakers and session process**
K. DeBeck, Canada
- 11:10 **Injection drug users' knowledge about overdose prevention and take home Naloxone in Ukraine**
*L. Shulga, A. Tokar
Ukraine*
- 11:20 **Transitions from concentrated HIV epidemics among people who inject drugs to self-sustained heterosexual HIV epidemics: results of a multi-country analysis**
*J. Feelemyer¹, D.C. Des Jarlais¹, K. Arasteh¹, S. Modi¹, H. Hagan¹, B. Mathers², L. Degenhardt²
¹United States, ²Australia*
- 11:30 **The role of drug policies: how science and policy can work together**
- 11:40 **Treatment and care for injecting drug users with HIV infection: a review of barriers and way forward**
P. Carrieri, France
- 11:50 **Questions and answers**
- 12:20 **Conclusion**

TUWS01 Strengthening Client and Patient Care: How to Reduce Stigma and Discrimination in Health Settings**Venue: Mini Room 1****Time: Tuesday 19 July, 11:00-14:00****Co-Facilitators: Laura Nyblade, United States
Evan Collins, Canada**

Level: Intermediate

Target Audience: HIV Health Care Workers of All Disciplines, Health Care Administrators and Clinic Directors, HIV Policy Planners and Decision Makers, Programme Managers, Policy-Makers, Community Organizers

Seating Limit: 50

Stigma and discrimination, in health care settings as well as the community, impedes access to HIV treatment, care and support, adherence, reduces quality of care, and undermines prevention efforts. Effective interventions and practical tools exist that address stigma reduction in health care settings across varying geographic and epidemic contexts. Using a mixture of participatory methods and presentations, this workshop will share current best practices and tools for reducing stigma and discrimination in health care settings that can be used to benefit health care workers, HIV positive clients and improve systems of care.

TUWS02 How to Conduct Operational Research and Implementation Science - Definitions, Design, Methodology**Venue: Mini Room 2****Time: Tuesday 19 July, 11:00-14:00****Co-Facilitators: Soumya Swaminathan, India
Laura Guay, United States**

Level: Foundation

Target Audience: Biomedical and Social Science Junior Researchers, Policy Makers and NGO Staff

Seating Limit: 70

The workshop will present definitions of operational research and implementation science and provide an overview of critical concepts in the sound research design and methodology for conducting operational research. An overview of the process of engaging in operational research and implementation science will be provided including how to identify a good research question, composition of a research team, research design and methodology (including qualitative methods), and dissemination of research results. Operational research and implementation science from the perspective of policy makers will be explicitly explored. The workshop will be interactive with short lectures interspersed with case studies, discussion around questions, and small group work.

TUBS01 Transition from Childhood to Adolescence**Bridging Session****Venue: Mini Room 4****Time: Tuesday 19 July, 11:00-12:30****Co-Chairs: Subhasree Sai Raghavan, India
Frances Cowan, Zimbabwe**

Adolescents account for 50% of new HIV infections worldwide, and fewer than 50% of this age group are able to identify ways of preventing HIV

transmission. Additionally with scaling up of large scale PMTCT and treatment programmes many affected and infected children who are born to HIV+ mothers are surviving into adolescence and adulthood. This session will discuss vulnerability to HIV infection and how to deliver integrated HIV, and SRH services for prevention of new infections among adolescents in different geographical regions. This session will also address how HIV affected adolescents are impacted by illness, stigma, disclosure, life-long treatment and death, as well as how health care professionals can support them while dealing with these challenges through integration of adolescent friendly services as part of the current paediatric and adolescent programmes.

- 11:00 **Introduction**
- 11:05 **Part 1: Enhancing prevention of HIV among adolescents**
- 11:05 **Update from recent advances**
A. Pettifor, United States
- 11:20 **Panel discussion**
R. Baggaley, Switzerland
L. Bekker, South Africa
A. Pettifor, United States
- 11:45 **Part 2: Addressing health, psychosocial and economic needs of HIV affected and infected children and adolescents**
- 11:45 **Update from recent advances**
D. Futterman, United States
- 12:00 **Panel discussion**
D. Futterman, United States
C. Haamujompa [TBC], Zambia
C. Luo, United States
D. Tindyebwa, Tanzania, United Republic of
- 12:25 **Conclusion**

Tuesday 19 July
13:00-14:00

TUSS01 Treatment as Prevention: Report Back from the Vancouver Workshop

Special Session

Venue: Session Room 1

Time: Tuesday 19 July, 13:00-14:00

Presentations to be confirmed.

TUSS02 European HIV/AIDS Research Programmes

Special Session

Venue: Session Room 2

Time: Tuesday 19 July, 13:00-14:00

Co-Chairs: Carlo Giaquinto, Italy

Patrice Debré, France

Support for HIV/AIDS research has always been an important component of the European Commission's activities and it has been implemented throughout the Research Framework Programme (FP). The overall aim is to structure and integrate European research by creating a close partnership between scientists and research teams from Europe and other parts of the world, as well as between industrial and public sector research. The FP-funded project portfolio ranges from basic science to preclinical and early clinical testing of new drugs and therapeutic approaches, microbicides and vaccine candidates, including the clinical management of HIV-infected individual. Furthermore, under FP6 and FP7 the European Commission (EC) is financing the European and Developing Countries Clinical Trials Partnership (EDCTP) where the EC with several EU Member States (MS) coordinate and jointly implement their research activities for capacity building and advanced clinical trials for HIV/AIDS, malaria and tuberculosis.

The session will start with a Commission presentation on the EU strategy and actions for HIV/AIDS research and how the research community can benefit from EC support, followed by four presentations from key selected projects identified as success stories funded under the FP and the EDCTP programmes.

- 13:00 **Introduction**
- 13:05 **EU strategy for HIV/AIDS and its implementation through the European Framework Programme**
A. Martini, Belgium
- 13:15 **NEAT - The European AIDS Treatment Network**
A. Pozniak, United Kingdom
- 13:25 **EuroCoord - European Network of HIV/AIDS Cohort Studies for a global coordination on clinical research**
C. Sabin, United Kingdom
- 13:35 **EUOPRISE - Network for Rational Design of HIV Vaccines and Microbicides**
B. Wahren, Sweden
- 13:45 **EDCTP Programme - European and Developing Countries Clinical Trials Partnership**
C. Mgone, Netherlands

13:55 **Conclusion**

TUPDB01 ART and Clinical Outcomes

Oral Poster Discussion

Venue: Session Room 3

Time: Tuesday 19 July, 13:00-14:00

Co-Chairs: Antonella d'Arminio Monforte, Italy

Francois Venter, South Africa

13:00 **HIV treatment guidelines and value of CD4 count at ART initiation: data analysis of a cohort of HIV patients enrolled in Italy when their CD4 count was >500 cells/mm³**

S. Lo Caputo¹, A. Cozzi-Lepri², A. Antinori¹, M. Galli¹, P.L. Viale¹, A. Lazzarin¹, G. Carosi¹, L. Sighinolfi¹, M. Montroni¹, A. D'Arminio Monforte¹

¹Italy, ²United Kingdom

13:05 **Monitoring and outcomes of ART: mathematical model based on IeDEA Southern Africa**

J. Estill¹, T. Hallett², D. Garone³, L. Johnson³, R. Wood³, M. Egger¹, O. Keiser¹

¹Switzerland, ²United Kingdom, ³South Africa

13:10 **Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1 infected naive patients with high CD4 counts**

S. Nozza, F. Canducci, L. Galli, A. Cozzi-Lepri, M.R. Capobianchi, E. Ceresola, A. Antinori, S. Di Giambenedetto, A. D'Arminio Monforte,

A. Castagna, ICONA Foundation

Italy

13:15 **Trend over calendar time in virological failure in HIV-infected patients treated for at least six months with combined antiretroviral therapy in France (FHDH ANRS CO04)**

C. Delaugerre, J. Ghosn, J.-M. Lacombe, G. Pialoux, L. Cuzin, O. Launay, A. Menard, P. de Truchis, D. Costagliola, FHDH ANRS CO04

France

13:20 **Are patients on HAART in Uganda experiencing less treatment failure than earlier anticipated? A case study of Mbarara RCE HAART clinic**

F. Kiweewa, A. Lugemwa, H. Namata, N. Musinguzi, W. Muyindiike, A.F. Nakirijja, C. Kityo, P. Mugenyi

Uganda

13:25 **Reaching 500 CD4 cells/ μ l is associated with higher survival after 9 months on ART in Sub-Saharan African patients**

D. Maman, M. Pujades-Rodriguez, S. Nicholas, M. McGuire, R. Ecochard, J.-F. Etard

France

13:30 **Moderated discussion**

TUPDA01 Molecular Virology and Host Restrictions Factors

Oral Poster Discussion

Venue: Mini Room 3

Time: Tuesday 19 July, 13:00-14:00

Co-Chairs: Giorgio Palù, Italy

Frank Kirchhoff, Germany

13:00 **HIV-1 genetic variability and intersubtype recombinant forms circulating in the North of Angola**

J.F. Machado de Morais Afonso^{1,2}, G. Bello¹, M. Guimarães¹, M. Sojka², M. Morgado¹

¹Brazil, ²Angola

13:05 **Next generation deep sequencing to evaluate viral tropism in HIV-1 patients exposed to maraviroc add-on therapy for eight days**

R.A. McGovern¹, A.F.Y. Poon¹, M. Lea², M. Genebat², E. Ruiz-Mateos², P.R. Harrigan¹

¹Canada, ²Spain

13:10 **Insertion of leucine-zipper motifs downstream of HIV-1 protease significantly reduces virion release**

Y.-Y. Pan, S.-M. Wang, C.-T. Wang

Taiwan, Province of China

13:15 **Replication capacities of chimeric NL4-3 encoding gag-protease from modern HIV-1 isolates are significantly reduced compared to those derived from isolates in the early days of epidemic in Japan**

S. Nomura, N. Hosoya, T. Kikuchi, M. Koga, H. Nakamura, T. Koibuchi, T. Fujii, A. Kawana-Tachikawa, A. Iwamoto, T. Miura

Japan

13:20 **Phylogenetic analysis of HIV-1 Gag cleavage sites polymorphism in HIV acutely infected patients**

E. Castro, M. Cavassini, P.-A. Bart, G. Pantaleo

Switzerland

13:25 **Critical role of calnexin in Nef-mediated inactivation of ABCA1**

L. Jennelle, T. Pushkarsky, M. Bukrinsky

United States

13:30 **Moderated discussion**

TUPDC01 Scaling Up Preventative Interventions

Oral Poster Discussion

Venue: Mini Room 4

Time: Tuesday 19 July, 13:00-14:00

Chair: Robert Bailey, United States

13:00 **Introduction**

13:05 **Delivering highly efficient male circumcision (MC) services for HIV prevention within the public sector in campaign mode in Iringa, Tanzania**

H.R. Mahler¹, B. Kileo¹, A. Hellar¹, S. Koshuma¹, M. Plotkin¹, M. Machaku¹, K. Curran², T. Adamu², E. Mpuya¹, E. Njeuhmeli²
¹Tanzania, United Republic of, ²United States

13:10 **Unmet need for family planning and low rates of dual method protection among men and women attending HIV care and treatment services in Kenya, Namibia and Tanzania**

R. Mbatia¹, G. Antelman¹, S. Pals², P. Bachanas², D. Carpenter¹, N. DeLuca³, O. Muhenje⁴, M. Sheriff¹, G. Arthur¹, B. Elul², and the 'HIV Prevention for PLHA: Evaluation of an Intervention Toolkit for HIV Care and Treatment Settings' Study Team
¹Tanzania, United Republic of, ²United States, ³Namibia, ⁴Kenya

13:15 **Estimated number and characteristics associated with perinatal HIV infections, 33 states, United States, 2003-2007**

A.W. Taylor, S. Nesheim, S. Whitmore, W. Ivy, M. Lampe, T. Kajese, R.L. Shouse
United States

13:20 **Service delivery and facility productivity during an integrated minor surgery/male circumcision pilot program in Mozambique**

M. Mahomed¹, J. Come¹, J.M. Felix¹, E. Necochea², D. Bossemeyer², B. Cummings¹, L. Nelson¹
¹Mozambique, ²United States

13:25 **Moderated discussion**

Tuesday 19 July
14:30-16:00

TUSY03 Overcoming Economic and Structural Barriers to HIV Prevention

Symposium

Venue: Session Room 1

Time: Tuesday 19 July, 14:30-16:00

Co-Chairs: Quarraisha Abdool Karim, South Africa
Catherine Hankins, Switzerland

The use of cash incentives to promote desired health outcomes is rapidly increasing and its role in reducing HIV infection is starting to emerge. This session will have experts in contingency management share their experiences in utilizing this approach in increasing treatment completion rates in substance users and school-going adolescents and to address gender and economic disparities. They will make their experience and expertise available for prevention scientists and intervention design.

14:30 **Introduction**

14:35 **Substance users**
M. Hull, Canada

14:50 **Structural interventions**
C. Watts, United Kingdom

15:05 **School-based interventions**
A. Pettifor, United States

15:20 **Questions and answers**

15:55 **Conclusion**

TUAA01 Antiviral Immunity and Transmission

Oral Abstract Session

Venue: Session Room 2

Time: Tuesday 19 July, 14:30-16:00

Co-Chairs: Michael Betts, United States
Guido Poli, Italy

14:30 **Penile infection of rhesus macaques with SIVmac251 recapitulates HIV-1 infection**
Z.-M. Ma, B. Keele, H. Qureshi, M. Stone, V. DeSilva, L. Fritts, J. Lifson, C. Miller
United States

14:40 **Host genetic determinants of innate immunity influence disease progression in HIV-1 infected children**
K. Gianesin, R. Freguja, M. Zanchetta, F. Carmona, S. Malacrida, O. Rampon, C. Giaquinto, A. De Rossi
Italy

14:50 **In vivo efficacy of HIV-specific T cells derived from engineered human hematopoietic stem cells**
S.G. Kitchen, B. Levin, V. Rezek, C. Aguilera-Sandova, O.O. Yang, J.A. Zack
United States

15:00 **Th22 cells constitute a highly HIV susceptible T cell subset that is associated with epithelial integrity in the sigmoid mucosa and systemic immune activation**

C. Kim, D. Chege, Z. Alidina, E. Benko, L. Shin, S. Huibner, C. Kovacs, G. Kandel, C. Kaushic, R. Kaul
Canada

15:10 **Maraviroc-resistant subtype B primary HIV-1 induced in vitro selection became highly sensitive to anti-gp120 neutralizing antibodies and autologous plasma IgG under high concentrations of the CCR5 inhibitor**
K. Yoshimura, S. Harada, A. Hamaji, S. Matsushita
Japan

15:20 **Moderated discussion**

TUSY04 Immune Activation/Inflammation and HIV Disease
Symposium

Venue: Session Room 3

Time: Tuesday 19 July, 14:30-16:00

Co-Chairs: Carla Pettinelli, United States
David Cooper, Australia

Currently there is significant interest in the role of chronic immune activation and inflammation as contributors to long-term co-morbidities observed in the setting of treated HIV infection. This session will explore the current state of knowledge about the pathogenesis of immune activation, highlighting what has been learned about the contributions of microbial translocation as an underlying mediator of immune activation. In addition, the relationship between both soluble and cellular measures of inflammation, coagulation and immune activation and measures of clinical disease, both end organ disease and metabolic complications will be reviewed. Finally, efforts to study potential interventions to reduce inflammation and immune activation in the setting of treated HIV will be evaluated.

14:30 **Introduction**

14:35 **Update on the pathogenesis of inflammation/immune activation and HIV in the setting of treated HIV disease**
S. Deeks, United States

14:50 **Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease**
J. Lundgren, Denmark

15:05 **Inflammation and metabolic complications in HIV disease**
G. Behrens, Germany

15:20 **Interventions to reduce inflammation and immune activation in treated HIV infection**
P. Hunt, United States

15:35 **Questions and answers**

15:55 **Conclusion**

TUWS03 Career Paths for Basic Scientists in Developing Countries

Venue: Mini Room 1

Time: Tuesday 19 July, 14:30-17:30

Co-Facilitators: Clive Gray, South Africa
Yiming Shao, China

Level: Foundation, Intermediate

Target Audience: Scientists in Basic Research, Clinical Research and Public Health Research, Clinicians, Novice and Intermediate Level Junior Staff, Students

Seating Limit: 50

This workshop has three main objectives. The first is to provide experience exchange and practical information on ways that young investigators in clinical and laboratory HIV research can harness early career development. The second is the introduction of funding resources and training opportunities for early career scientists in developing countries. The third is to identify and discuss the priorities in HIV research and their impact on early career funding. The workshop will begin with a series of short presentations from experts in the field from various training programmes and early career scientists. Participants will be asked to prioritize their career objectives and contribute to round table discussions.

TUWS04 What Does the Combination of HIV Prevention Look Like for Injecting Drug Users?

Venue: Mini Room 2

Time: Tuesday 19 July, 14:30-16:00

Co-Facilitators: Don C. Des Jarlais, United States
Adeeba Kamarulzaman, Malaysia

Level: Intermediate, Advanced

Target Audience: Community Based Organization Staff, Researchers on Policy, Professionals working on HIV and Drug Use

Seating Limit: 50

The workshop will focus on the use of combined HIV prevention programmes to reduce HIV transmission among people who inject drugs. The basis theories of combined prevention programmes - risk elimination and herd immunity - will be discussed. "Well studied" interventions such as needle/syringe programmes, drug dependence treatment, and ART will be examined. Needed coverage levels, barriers to large-scale implementation and barriers to the coordination of programmes will be addressed through examples in different countries and cities. The role of potential new programmes such as pre-exposure prophylaxis and programmes to reduce initiation into drug injecting will also be considered. Workshop participants will be encouraged to apply these programmes to their local situations and discuss these applications with the group.

TUAB02 Maternal Health and Paediatric Outcomes
Oral Abstract Session

Venue: Mini Room 4

Time: Tuesday 19 July, 14:30-16:00

Co-Chairs: Avy Violari, Zambia
Michael Tolle, Botswana

- 14:30 **Is highly active antiretroviral therapy (HAART) in pregnancy protective against maternal mortality? Results from a large DREAM cohort in Malawi and Mozambique**
G. Liotta¹, S. Mancinelli¹, E. Gennaro¹, P. Scarcella¹, K. Nielsen Saines², N.A. Magid³, P. Germano¹, J. Haswell⁴, G. Guidotti¹, E. Buonomo¹, A.M. Doro Altan¹, L. Palombi¹, M.C. Marazzi¹
¹Italy, ²United States, ³Mozambique, ⁴Malawi
- 14:40 **Peripartum valacyclovir improves markers of HIV-1 disease progression in women co-infected with HSV-2: a randomized trial**
A.C. Roxby¹, A.L. Drake¹, F. Ongecha-Owuor², B.A. Richardson¹, J.N. Kiarie², G.C. John-Stewart¹, C. Farquhar¹
¹United States, ²Kenya
- 14:50 **Time to HIV DNA-PCR positivity according to maternal/infant antiretroviral prophylactic regimen in non-breastfed HIV-infected infants in populations with predominantly non-B HIV subtype: a collaborative analysis of data from cohorts in Thailand, South Afr**
D.E. Shapiro¹, R. Balasubramanian¹, M.G. Fowler², K. Dominguez¹, P. Tookey³, J. Masters³, J. Tosswill³, M. Lallemand⁴, M. McConnell⁴, P. Mock⁴, G. Sherman⁵, S. Lockman¹, V. Novitsky¹, P. Palumbo¹, S. Nesheim¹, B. Bohannon¹, K. Rich¹, M. Hughes¹, International Collaborative Study of Pediatric HIV Diagnostic Tests
¹United States, ²Uganda, ³United Kingdom, ⁴Thailand, ⁵South Africa
- 15:00 **Variability of growth response in children on antiretroviral treatment: the TeDEA Southern Africa Collaboration**
T. Gsponer¹, R. Weigel^{2,3}, M.-A. Davies⁴, K. Technau⁴, B. Eley⁴, D. Gorone⁴, H. Moultrie⁴, M. Egger¹, O. Keiser¹
¹Switzerland, ²United Kingdom, ³Malawi, ⁴South Africa
- 15:10 **Population HIV-free survival among HIV-exposed children in four African countries: the PEARL community survey**
P. Tih¹, D. Coetzee², D.K. Ekouevi^{3,4}, K. Stinson², E. Stringer^{5,6}, T. Creek⁶, M. Giganti^{5,6}, T. Welty¹, N. Chintu^{5,6}, B.H. Ch^{5,6}, F. Dabis⁴, C. Wilfert⁶, N. Shaffer², J.S.A. Stringer^{5,6}
¹Cameroon, ²South Africa, ³Cote D'Ivoire, ⁴France, ⁵Zambia, ⁶United States, ⁷Switzerland
- 15:20 **Moderated discussion**

Tuesday 19 July
16:30-18:00

TUBS02 Use of Antivirals in Prevention - Current Challenges and Controversies

Bridging Session

Venue: Session Room 1

Time: Tuesday 19 July, 16:30-18:00

Co-Chairs: Chris Beyrer, United States
Glaudina Loots, South Africa

Use of Antivirals in prevention brings together disciplines and speakers from Tracks A, B, C and D. The concept is to look at the "big picture" questions of the potential use of anti-viral drugs, including for oral and topical (vaginal and rectal) chemoprophylaxis, HAART's role(s) in prevention, use of post-exposure prophylaxis, and the synergies and challenges in implementation science and challenges to scale up of ARV-based prevention approaches. Speakers will be asked to address controversies, challenges including ARV resistance, adherence, cost-effectiveness, and programmatic challenges to these potential approaches.

- 16:30 **Introduction**
- 16:35 **Treatment as prevention**
N. Padian, United States
- 16:50 **Oral and topical prophylaxis**
I. McGowan, United States
- 17:05 **Community and advocacy perspectives on ARV for prevention**
M. Warren, United States
- 17:20 **Regulatory and ethical issues for ARV-based prevention**
T. Farley, Switzerland
- 17:35 **Moderated discussion**
T. Farley, Switzerland
D. Haerry, Belgium
I. McGowan, United States
N. Padian, United States
M. Warren, United States
- 17:55 **Conclusion**

TUSY05 Ten Years of Scaling Up HIV Treatment and Care: Translating the Vision Towards Universal Access

Symposium

Venue: Session Room 2

Time: Tuesday 19 July, 16:30-18:00

Co-Chairs: Michel Kazatchkine, Switzerland
Eric Goosby, United States

The year 2011 marks the end of a decade of impressive scale-up of the global AIDS response. In 2000, critical actions by political leadership and strong civil society movement led to dramatic expansion of the global HIV/AIDS response. These include the 2000 Durban AIDS Conference which called for HIV treatment scale-up in developing countries, the Kyushu-Okinawa G8 Summit Meeting 2000 where it was agreed to strengthen measures against the three infectious diseases of HIV/AIDS, tuberculosis and malaria, the UN Millennium Declaration adopted by world leaders at the Millennium Summit in September 2000 which called for concrete action against HIV/AIDS (MDG 6), and the UN General Assembly which decided in November 2000 to hold a Special Session on HIV/AIDS at the highest political level. These actions subsequently led to the 2001 Declaration of Commitment on HIV/AIDS, The Global Fund to Fight AIDS Tuberculosis and Malaria established in 2002, and the 2005 Gleneagles G8 Summit commitment to develop and implement a package for HIV treatment and care aimed at Universal Access to treatment for all those who need it by 2010. As a result, global AIDS funding was significantly scaled-up and by the end of December 2010, over 5.2 million people were receiving life-saving antiretroviral therapy. Despite the progress made there are still 1.8 million HIV-related deaths and 2.6 million new infections per year. Two-thirds of people who need treatment are still without access, and yet pressure on global HIV funding is continuing to increase. In a fragile economic climate, political leadership on the global AIDS response has declined compared to a decade ago. The purpose of this session is to take stock and reflect on progress achieved over the last decade, highlight innovations and evidence informing new strategies to improve effectiveness and efficiency of the global AIDS response, and sustain scale-up towards Universal Access in the next decade.

- 16:30 **Introduction**
- 16:35 **Part 1: Progress achieved and the way forward**
- 16:35 **Smart investments to save more lives: efficiencies, innovation, impact**
C. Holmes, United States
- 16:43 **New Global Fund strategy**
- 16:51 **Part 2: Strategy and goals**
- 16:51 **Treatment 2.0**
B. Schwartländer, Switzerland
- 16:59 **The sustainable health sector response**
C. McClure, Switzerland
- 17:07 **Part 3: Translation**
- 17:07 **Translating vision and strategies into the real world: Malawi**
Z. Chirwa, Malawi
- 17:15 **Translation vision and strategies into the real world: Botswana**
K. Seipone, Botswana
- 17:23 **Translating vision and strategies into the real world: community perspective**
L. Dlamini [TBC], South Africa
- 17:31 **Questions and answers**
- 17:56 **Conclusion**

TUAD01 Retention in the Care Cascade
Oral Abstract Session

Venue: Session Room 3

Time: Tuesday 19 July, 16:30-18:00

Co-Chairs: Robin Wood, South Africa
Louise Kuhn, South Africa

- 16:30 **Empowering the community to address the needs of HIV-positive youth in a district of post-conflict Northern Uganda**
S.P. Akena, D. Sera, F. Oburu, L. Ciccio
Uganda
- 16:40 **Integration of HIV treatment in primary health care centers impacts attrition from HIV treatment programs in Central Mozambique**
B.H. Lambdin¹, M.A. Micek¹, T. Koepsell¹, J.P. Hughes¹, A. Stergachis¹, K. Sherr¹, M. Karagianis², S. Gloyd¹, J. Lara¹, S. Gimbel¹, J. Pfeiffer¹
¹United States, ²Mozambique
- 16:50 **Community adherence support sustains improved three year outcomes for children on ART**
A. Grimwood, G. Fatti, P. Bock, E. Mothibi, M. Malahlela, A. Jason
South Africa
- 17:00 **Mothers2mothers': Let's SOAR: strengthening outcomes by analyzing results: building local capacity for data analysis and use to improve PMTCT-plus outcomes as part of continuous quality improvement (CQI)**
A. Myers, A. Gips, M. Patose, M. Mosoeu, M. Nolan, M. Besser
South Africa
- 17:10 **WHO HIV drug resistance early warning indicators as treatment program monitoring and evaluation tool in Central American countries**
G. Ravasi¹, M.D. Pérez-Rosales², V.M. Mejía Cruz², K. Zepeda³, M.E. Pérez², R. Aguilar⁴, K. Ramos⁵, O. Sued⁶, M. Alonso Gonzalez⁶, K. Israel⁶
¹Brazil, ²El Salvador, ³Honduras, ⁴Nicaragua, ⁵Guatemala, ⁶United States

TUAC01 Prevention for Most At-Risk Populations**Oral Abstract Session****Venue:** Mini Room 4**Time:** Tuesday 19 July, 16:30-18:00**Co-Chairs:** Patrizia Carrieri, France

Frits van Griensven, Thailand

- 16:30 **Population-based estimates of prevalence of HIV, HBV and HCV and HIV-related risk behaviors in male injection drug users in Lagos, Nigeria**
W. Tun¹, L. Abiodun², L. Vu¹, M. Sheehy¹, A. Karlyn¹, J. Njab², S. Adebajo², J. Anyanti², O. Amadi²
¹United States, ²Nigeria
- 16:45 **Gender analysis of sexual violence against patients with severe psychiatric illness**
H.N. Oliveira, C.J. Machado, M.D.C. Guimarães
Brazil
- 17:00 **HIV incidence and associated risk factors among female sex workers in a high HIV-prevalence area of China**
K. Reilly^{1,2}, H. Wang¹, K. Brown¹, X. Jin¹, J. Xu¹, G. Ding¹, C. Zang¹, J. Wang¹, N. Wang¹
¹China, ²United States
- 17:15 **Risk compensation and pre-exposure prophylaxis (PrEP): a post-iPrEx survey of US men who have sex with men (MSM)**
R. Irvin, A. Liu, L. Kroboth, E. Vittinghoff, R. Tarver, P. Sullivan, S. Golub, B. Koblin, S. Buchbinder
United States
- 17:30 **Multilevel determinants of women's HIV risk in the United States: qualitative implications for intervention development from the HIV Prevention Trial Network's (HPTN) Women's HIV SeroIncidence Study (ISIS)**
P.M. Frew, C. del Rio, A. O'Leary, I. Kuo, J. Justman, D. Haley, W. Chege, C. Golin, A. Adimora, C. Root, H. Waller, L. Jones, K. Lancaster, J. Lucas, A. Amsterdam, S. Hodder, for the HIV Prevention Trials Network Women's HIV SeroIncidence Study (ISIS) Team
United States
- 17:45 **Moderated discussion**

Tuesday 19 July
18:30-20:30

TUSA05 IAS Members' Meeting: Thirty Years Into the AIDS Epidemic - What are the Next Steps?**Non-Commercial Satellite****Venue:** Session Room 3**Time:** Tuesday 19 July, 18:30-20:30**Chair:** Bertrand Audoin, Switzerland

Conference delegates are invited to participate in this satellite session which also serves as the IAS General Members' Meeting. An update will be given on the progress of the IAS's strategic priorities for 2010 to 2014. There will also be presentations around the commemoration of 30 years of HIV/AIDS, followed by a discussion.

- 18:30 **Welcome remarks and update**
E. Katabira, Uganda
B. Audoin, Switzerland
- 19:00 **Achievements and learning over the past 30 years: what do we need next?**
F. Barré-Sinoussi, France
- 19:15 **Next steps towards universal access and ways forward to implementing recent findings in the global South**
E. Katabira, Uganda
- 19:30 **How low- and middle-income countries see the next 30 years of the AIDS epidemic, focusing on Asia**
V. Nguyen, Viet Nam
- 19:45 **Questions and answers with discussion**

TUSA06 NIH Grantsmanship Workshop**Non-Commercial Satellite****Venue:** Mini Room 1**Time:** Tuesday 19 July, 18:30-20:30

This workshop will provide an overview of NIH-sponsored AIDS research, AIDS research priorities, the electronic submission process for grant applications, the peer review process, information on how to prepare a successful grant application, and a summary of key international AIDS research and training programs.

- 18:30 **Welcome and Overview of NIH AIDS Research Program**
- 18:40 **Electronic Submission of Grant Applications**
- 18:55 **CSR Peer Review of NIH AIDS Applications**
- 19:05 **Presentations by NIH Institute and Center Program Directors 1: National Institute of Allergy and Infectious Diseases**

- 19:15 **Presentations by NIH Institute and Center Program Directors 2: National Institute on Drug Abuse**
- 19:25 **Presentations by NIH Institute and Center Program Directors 3: National Institute of Mental Health**
- 19:35 **Presentations by NIH Institute and Center Program Directors 4: Eunice Kennedy Shriver National Institute of Child Health and Human Development**
- 19:45 **Presentations by NIH Institute and Center Program Directors 5: National Cancer Institute**
- 19:55 **Presentations by NIH Institute and Center Program Directors 6: National Institute on Alcohol Abuse and Alcoholism**
- 20:05 **Discussion**

TUSA07 HIV-2: A Model of Attenuated HIV Infection

Non-Commercial Satellite

Venue: Mini Room 2

Time: Tuesday 19 July, 18:30-20:30

HIV-2 infection is less frequent than HIV-1 but affects one to two million people, mostly West African patients. Understanding the virus and host mechanisms of this model of attenuated retroviral infection could lead to identify potential means to control HIV infection.

Clinical research endpoints and treatment guidelines defined for HIV-1 do not fit and apply to the characteristics of HIV-2 infection and the gold standard therapy remains to be determined through collaborative studies. The seminar aims to present updated data on virological, immunological, and North-South clinical research on this infection.

- 18:30 **HIV-2 : Overview (Epidemiology, Transmission, Viral load, Variability)**
- 18:45 **Molecular characteristics of HIV-2**
- 18:55 **Immunological Response to HIV-2 Infection**
- 19:05 **Discussion**
- 19:15 **Virology Case Management (Viral load, Resistance, Tropism)**
- 19:25 **Clinical Case Management**
- 19:35 **Discussion**
- 19:45 **ANRS immuno-virological HIV-2 Network**
- 19:55 **ACHIEV2E, COHERE and EuroCoord**
- 20:05 **International Epidemiologic Databases to Evaluate AIDS and RESAPSI**
- 20:15 **Conclusion and final discussion**

TUSA08 Can We End the Epidemic?

Non-Commercial Satellite

Venue: Mini Room 3

Time: Tuesday 19 July, 18:30-20:30

With the rates of new HIV infections continuing to outpace the number of individuals who are able to start treatment, a global HIV prevention and treatment revolution is needed. Recent breakthrough clinical trials of topical microbicides, oral pre-exposure prophylaxis (PrEP) and vaccines show that each can reduce HIV infections. At the same time, encouraging news about medical male circumcision rollout programs and behavioral change in severely impacted countries has also led to a renewed focus on combination approaches to reduce HIV.

As research brings us closer to having the additional tools to lead a global prevention and treatment revolution, the question remains: How to do we translate promising starts into real solutions that can end the epidemic?

This interactive satellite session brings together global leaders in HIV prevention and treatment to discuss with the audience how to start and sustain a comprehensive HIV revolution that could end AIDS.

Proposed Panelists to

Wednesday 20 July

08:55-10:30

WEPL01 Wednesday Plenary Session

Plenary

Venue: Session Room 1

Time: Wednesday 20 July, 08:55-10:30

Co-Chairs: Adeeba Kamarulzaman, Malaysia

Leonardo Palombi, Italy

Gottfried Hirnschall, Switzerland

08:55 **IAS-NIDA Fellowship Award Ceremony**

- 09:00 **Ending HIV Transmission Among Drug Users by 2015**
N. Volkow, United States
- 09:25 **Caring for Mothers and Children: Towards the Millennium Development Goals**
P. Musoke, Uganda
- 09:50 **Towards an HIV Cure**
E. Verdin, Belgium

Wednesday 20 July
11:00-12:30

WESY01 Towards an HIV Cure: New Strategies for an Old Challenge

Symposium

Venue: Session Room 1

Time: Wednesday 20 July, 11:00-12:30

Co-Chairs: Una O'Doherty, United States
Christine Rouzioux, France

This session aims at presenting novel strategies being explored to address the challenge of HIV persistence under antiretroviral therapy and find a solution to control HIV reservoirs in order to achieve at least a functional cure to HIV infection. This session will look at the immunopathogenesis of HIV persistence, innate and adaptive immune control of HIV reservoirs and strategies based on drug development and/or immune therapies to reduce or eliminate HIV reservoirs. The session will also look at which new tools and technologies have to be developed to measure HIV DNA in vivo and will highlight ethical questions linked to novel clinical trials.

- 11:00 **Introduction**
- 11:05 **New concept in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference**
N. Chomont, United States
- 11:20 **Aptamer targeted RNAi for new delivery and therapeutic strategies in HIV infection**
J. Rossi [TBC], United States
- 11:35 **Drug development**
D. Hazuda, United States
- 11:50 **HIV persistence and innate immune control**
M. Benkirane, France
- 12:05 **Quantifying the HIV reservoir in vivo: current and future tools**
J. Wong, United States
- 12:20 **Questions, answers and conclusion**

WEAX01 The TB Paradox

Oral Abstract Session

Venue: Session Room 2

Time: Wednesday 20 July, 11:00-12:30

Co-Chairs: Ndeye Coumba Toure Kane, Senegal
Massimo Galli, Italy

- 11:00 **Introduction**
M. Galli, Italy
- 11:10 **Prevalence of MDR-TB amongst patients with HIV and TB co-infection seen at the DOTS clinic of Nigerian Institute of Medical Research (NIMR)**
V.N.V. Enya, C. Onubuogu, M.O. Wahab, L.O. Efere, B.O. Motayo, P.O. Nwadike, N. Onyejebu, T.Y. Raheem, U.T. Igbasi, N.E. Tochukwu, N.N. Nwokoye, C.N. Kunle-Ope, O. Ejezie, R.M. Omoloye, E.O. Idigbe
Nigeria
- 11:20 **Activation of the CREB-dependent pathway distinguishes *M.tuberculosis*-mediated immune reconstitution syndrome (IRIS) from chronic HIV and HIV-MTB co-infection**
N. Dawany¹, A. Kossenkov¹, C. Chang¹, F. Conradie², I. Sanne², L.J. Montaner¹, L. Showe¹, L. Azzoni¹
¹United States, ²South Africa
- 11:30 **Incidence and risk factors of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in HIV-infected adults enrolled in the CAMELIA clinical trial (ANRS 1295/12160 – CIPRA KH001/10425)**
D. Laureillard^{1,2}, O. Marcy¹, Y. Madec³, S. Chan¹, L. Borand¹, N. Prak¹, C. Kim¹, K.K. Lak¹, C. Hak¹, B. Dim¹, E. Nerrienet¹, T. Sok¹, A.E. Goldfeld^{1,4}, F.X. Blanc³
¹Cambodia, ²Viet Nam, ³France, ⁴United States
- 11:40 **Immune reconstitution inflammatory syndrome following antiretroviral therapy initiation during tuberculosis treatment**
K. Naidoo¹, N. Jithoo¹, N. Yende¹, N. Padayatchi¹, K. Naidoo¹, S. Abdool Karim^{1,2}
¹South Africa, ²United States
- 11:50 **Moderated discussion**
-

WESY02 The Impact of the Economic Crisis on HIV Programmes: Is Integration of Services and Operational Research the Solution?
Symposium

Venue: Session Room 3

Time: Wednesday 20 July, 11:00-12:30

Co-Chairs: Gcebile Ndlovu, South Africa
Robert Oelrichs, United States

The session will examine solutions to the detrimental impact of the current economic crisis which threatens sustainability of funding for HIV programmes, discuss how efficiency gains facilitated by better integration of HIV programmes with other MDG-related programmes and health systems strengthening are part of the solution, and advocate further scaling up of resources in addition to these efficiency gains for reaching universal access by 2015.

11:00 **Introduction**

11:05 **Financing the response to HIV in low- and middle-income countries: how it is affected by the economic crisis**
R. Greener, Switzerland

11:20 **Global health funding and national HIV programmes: which synergies?**

11:35 **Decentralization of HIV care in sub-Saharan Africa: lessons for resource allocation**
F. Eboko, France

11:50 **Panel discussion**
K. De Cock [TBC], United States
F. Eboko, France
W. El-Sadr, United States
E. Goosby, United States
R. Greener, Switzerland
K. Lezhentsev, Ukraine
M. Raviglione, Switzerland

12:25 **Conclusion**

WEWS01 Identifying Current and Potential Ethical Challenges and Dilemmas in HIV Prevention Research

Venue: Mini Room 2

Time: Wednesday 20 July, 11:00-12:30

Co-Facilitators: Andrew Lambert, South Africa
Raffaella Ravinetto, Belgium

Level: Intermediate

Target Audience: Physicians, Nurses, Laboratory Staff, Social Scientists, and Clinicians with Experience or an Interest in HIV Prevention Research. Community Advocates, Members of Institutional Review Boards/Ethics Committees, Donors' Representatives, Research/Trial Sponsors
Seating Limit: 50

Conciliating the objectives of medical research with the interests and wellbeing of participants and their communities is always a challenge. Ethics committees and researchers are guided in their choices by internationally recognized guidelines, including the Declaration of Helsinki, Belmont report, WHO and ICH Good Clinical Practices, CIOMS Guidelines etc. However, most guidelines were developed before 1996 and in the framework of clinical trials, so they may fail to fully address other questions, e.g. ethical aspects of research in prevention, vulnerability of groups and communities (not only of individuals), weakness of ethical/ regulatory overview etc. Similarly, they may fail to consider the perspectives of "new" research actors: communities, non-commercial sponsors, and donors.

Researchers in HIV prevention may be especially exposed to ethical dilemmas linked to these aspects. There are newly emerging ethical concerns as the HIV prevention field further develops and adapts to the current trend towards combination HIV prevention packages and combination studies. This workshop aims to help participants identify "especially challenging situations" in the current field of HIV prevention research. Participants will have an opportunity to propose context-adapted approaches, including, but not limited to what concerns the ethical review, the vulnerability of communities, the co-ownership of communities, issues of confidentiality and standard of care and the role played by external donors.

WEAA01 Models of Protection

Oral Abstract Session

Venue: Mini Room 4

Time: Wednesday 20 July, 11:00-12:30

Co-Chairs: Santiago Perez, Mexico
Donald Sodora, United States

11:00 **Introduction**

11:05 **Influence of the functional profile of Gag and Nef specific CD8+ T cells and the bacterial translocation on the activation levels on central-memory CD8+T cells in elite controllers**
M. Lopez, A. Peris, V. Soriano, S. Lozano, N.I. Rallón, C. Restrepo, J. Gonzalez-Lahoz, J.M. Benito
Spain

11:15 **An intrinsic inhibitor of p-TEFb and HIV-1 transcriptional elongation in CD4 T cells from elite controllers**
M. Buzon, C. Li, J. Huang, T. Cung, K. Seiss, J. Beamon, M.F. Carrington, F. Pereyra, E. Rosenberg, X.G. Yu, M. Lichterfeld
United States

11:25 **Reduced susceptibility to SIV infection in central-memory CD4+ T-cells of sooty mangabeys: a key mechanism for AIDS resistance?**
B. Cervasi¹, M. Paiardini¹, L. Micci¹, E. Reyes-Aville¹, F. Kirchhoff², R. Collman¹, J. Brenchley¹, G. Silvestri¹
¹United States, ²Germany

- 11:35 **Double negative T cells in sooty mangabeys maintain helper T cell function during SIV infection**
V. Sundaravaran, M. Gasper, J. Brenchley, J. Else, G. Silvestri, D. Sodora
United States
- 11:45 **Experimentally induced depletion CD25+CD4+ T regulatory cells during acute SIVagm infection prevent acute-to-chronic resolution of immune activation, control of viral replication and impairs CD4+ T cell restoration in natural hosts of SIVs**
I. Pandrea, T. Gafuin, R. Gautam, D. Mandell, A. Lackner, C. Apetrei
United States
- 11:55 **Questions and answers**

Wednesday 20 July
13:00-14:00

WEPDB01 ART and New Strategies

Oral Poster Discussion

Venue: Session Room 2

Time: Wednesday 20 July, 13:00-14:00

Co-Chairs: Christine Katlama, France

Andrea Antinori, Italy

- 13:00 **24-week efficacy, safety, tolerability, and pharmacokinetics (PK) of darunavir/ritonavir (DRV/r) once daily (qd) in treatment-naïve adolescents aged 12 to < 18 years in DIONE**
P. Flynn¹, S. Blanche², C. Giaquinto³, S. Komar⁴, A. Noguera-Julian⁵, S. Welch⁶, E. Lathouwers⁷, T. Van de Casteele⁷, P. Vis⁷, M. Opsomer⁷
¹United States, ²France, ³Italy, ⁴Ukraine, ⁵Spain, ⁶United Kingdom, ⁷Belgium
- 13:05 **Sustained efficacy and tolerability of raltegravir after 240 weeks of combination ART in treatment-naïve HIV-1-infected patients; final analysis of protocol 004**
E. Gotuzzo¹, B.-Y. Nguyen², M. Markowitz², F. Mendo¹, W. Ratanasuwana³, C. Lu², S. Bhanja², H. Tepler², for the Protocol 004 Study Team
¹Peru, ²United States, ³Thailand
- 13:10 **Virological efficacy of the four tenofovir-containing WHO-recommended regimens for initial antiretroviral therapy**
M. Tang, P. Kanki, R. Shafer
United States
- 13:15 **Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort (2004-2008)**
P. Morlat, A. Vivot, F. Dauchy, J. Asselineau, M.-A. Vandenhende, E. Lazaro, Y. Gérard, F. Bonnet, D. Neau, P. Mercié, E. Déti, G. Chêne, Groupe d'Epidémiologie Clinique du SIDA en Aquitaine
France
- 13:20 **Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART (phase II ISS T-002)**
B. Ensoli, S. Bellino, A. Tripiciano, O. Longo, V. Francavilla, S. Marcotullio, A. Cafaro, O. Picconi, G. Panizza, A. Scoglio, A. Arancio, C. Ariola, M.J. Ruiz Alvarez, M. Campagna, D. Scaramuzzi, C. Iori, R. Esposito, C. Mussini, F. Ghinelli, L. Sighinolfi, G. Palamara, A. Latini, G. Angarano, N. Ladisa, F. Soscia, V.S. Mercurio, A. Lazzarin, G. Tambussi, R. Visintini, F. Mazzotta, M. Di Pietro, M. Galli, S. Rusconi, G. Carosi, C. Torti, G. Di Perri, S. Bonora, F. Ensoli, E. Garaci
Italy
- 13:25 **High-dose valacyclovir suppressive therapy results in greater reduction in plasma HIV-1 levels compared to standard dose acyclovir suppression among HIV-1/HSV-2 co-infected persons: a randomized, open-label, crossover trial**
K. Mugwanya^{1,2}, J. Baeten², N. Mugo^{2,3}, E. Irungu^{2,3}, K. Ngure³, C. Celum²
¹Uganda, ²United States, ³Kenya
- 13:30 **Moderated discussion**

WEPDA02 Drug Development and Resistance

Oral Poster Discussion

Venue: Session Room 3

Time: Wednesday 20 July, 13:00-14:00

Co-Chairs: Mark A. Wainberg, Canada

Christophe Vanpouille, United States

- 13:00 **Introduction**
M. Andreoni, Italy
- 13:05 **Explaining the CAPRISA 004 results: tenofovir as a double-targeted HIV-1/HSV-2 antiviral**
A. Graciela¹, A. Lisco², C. Vanpouille², E. Balestra³, J. van den Oord¹, T. Cihlar², C.-F. Perno³, R. Snoeck¹, L. Margolis², J. Balzarini¹
¹Belgium, ²United States, ³Italy
- 13:10 **HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism**
M. Roche¹, M.R. Jakobsen¹, J. Sterjovski¹, A. Ellett¹, F. Posta², B. Lee², B. Jubb³, M. Westby³, S.R. Lewin¹, P.A. Ramsland¹, M.J. Churchill¹, P.R. Gorry¹
¹Australia, ²United States, ³United Kingdom

- 13:15 **HIV-1 evolution and drug-resistance among patients receiving antiretroviral therapy (ART) in San Mateo County, California, 1997-2010**
S. Dalaj, S. Sethi, V. Levy, D. Katzenstein
United States
- 13:20 **Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 *env* gene influences HIV replication and evolution *in vivo***
A. Pasternak¹, N. Korokhov², B. Berkhout¹, V. Lukashov¹, L. Humeau²
¹Netherlands, ²United States
- 13:25 **Effects of HIV integrase polymorphisms on raltegravir-resistance susceptibility**
H. Suzuki, M. Maejima, J. Hattori, M. Nishizawa, S. Ibe, Y. Yokomaku, Y. Iwatani, W. Sugiura
Japan
- 13:30 **Moderated discussion**

WEPDD01 The Integration Imperative: HIV Services and Health Systems

Oral Poster Discussion

Venue: Mini Room 1

Time: Wednesday 20 July, 13:00-14:00

Co-Chairs: Haileyesus Getahun, Switzerland

James Hakim, Zimbabwe

- 13:00 **Evidence of an emerging practice: integrating the basic care and prevention package (BCP) into care and treatment services for HIV-positive people in Uganda**
S. Sensalire, P. Buyungo, S. Kambabazi Lubaale, S. Mpanga Mukasa, M. Kaggwa, D. Balaba
Uganda
- 13:05 **Increasing access to HIV counselling and testing (HCT), providing early detection and access to care: a community HCT model for integrated HIV and TB testing in Cape Town, South Africa**
S.-A. Meehan, N. Beyers, P. Naidoo
South Africa
- 13:10 **Integration of HIV and TB services results in earlier and more prioritised ART initiation in Uganda**
S.M. Hermans^{1,2}, B. Castelnuovo¹, A. Kambugu¹, J.M.A. Lange², A.I.M. Hoepelman², Y.C. Manabe^{1,3}
¹Uganda, ²Netherlands, ³United States
- 13:15 **Strengthening health systems for chronic care and non-communicable diseases (NCDs): leveraging HIV programs to support diabetes services in Ethiopia**
Z. Melaku¹, A. Reja¹, M. Rabkin²
¹Ethiopia, ²United States
- 13:20 **Uptake of HIV services in combination with malaria prevention and family planning (FP) services at ante-natal care (ANC) clinics in Northern Uganda**
D. Sera, L. Ciccio, M. Makumbi, A. Ocerro
Uganda
- 13:25 **Missed opportunity of HIV prevention among male sexually assaulted survivors in South Africa**
E. Mbizvo, M. Madena, S. Mullick, M. Menziwa
South Africa
- 13:30 **Moderated discussion**

WEPDA01 HIV Co-Infections: The Axis of Evil

Oral Poster Discussion

Venue: Mini Room 2

Time: Wednesday 20 July, 13:00-14:00

Co-Chairs: William H. Carr, South Africa

Nicole Ngo-Giang Huong, Thailand

- 13:00 **Compartmentalisation of natural killer cell responses in the central nervous system during human cryptococcal meningitis/ HIV co-infection**
V. Naranbhai¹, C.C. Chang^{1,2}, R. Durgiah¹, A. Lim², M.-Y. Moosa¹, T. Ndung'u¹, J. Elliott², S.R. Lewin², M.A. French², W.H. Carr^{1,3}
¹South Africa, ²Australia, ³United States
- 13:05 **Placental malaria and mother-to-child transmission of human immunodeficiency virus-1 in rural Rwanda**
P. Bulterys¹, A. Chao², S. Dalai¹, C. Zink¹, A. Dushimimana³, D. Katzenstein¹, A. Saah¹, M. Bulterys²
¹United States, ²Rwanda, ³Congo, the Democratic Republic of the
- 13:10 **GBV-C infection reduces B cell and NK cell activation markers and monocyte CCR5 surface expression**
J.T. Stapleton, K. Chaloner, J. Zhang, D. Klinzman, J. Martinson, J. Xiang, W. Wallace, S. Desai, A. Landay
United States
- 13:15 **CD4⁺ and CD8⁺ T-cells co-expressing CXCR3 and CCR5 are increased in the cerebrospinal fluid relative to blood of HIV-infected patients with cryptococcal meningitis and associated with cryptococcal immune reconstitution inflammatory s**
C.C. Chang^{1,2}, A. Lim¹, S. Omarjee², J.H. Elliott¹, B.I. Gosnell², W.H. Carr², Y. Moosa², T. Ndung'u², S.R. Lewin¹, M.A. French¹
¹Australia, ²South Africa
- 13:20 **Destruction of nervous cells is potentiated in the simultaneous presence of gp41 and *Toxoplasma gondii***
E.E. Escobar Guevara, Y.J. Fuentes Alvarado, J.A. Carrero Salas, Y.B. Roldán Dávila, B. Alarcón de Noya, M.E. de Quesada, M.A. Alfonso Díaz
Venezuela

13:25 **HIV-2 infection and HTLV-1 infection are associated with substantially increased mortality in a rural West African community**
C. van Tienen^{1,2}, M. Schim van der Loeff², I. Peterson¹, M. Cotten¹, S. Andersson³, B. Holmgren³, T. Vincent⁴, T. de Silva¹, S. Rowland-Jones⁴, P. Aaby⁵, H. Whittle¹
¹Gambia, ²Netherlands, ³Sweden, ⁴United Kingdom, ⁵Guinea-Bissau

13:30 **Moderated discussion**

WEPDC01 Behavioural Disinhibition and Predictors of HIV Risk

Oral Poster Discussion

Venue: Mini Room 3

Time: Wednesday 20 July, 13:00-14:00

Chair: Susan Buchbinder, United States

13:00 **Introduction**

13:05 **Formal network analyses illuminate opportunities for personal network intervention on sex and sex drug use behavior of African American men who have sex with men (AA-MSM)**

J.A. Schneider, B. Cornwell, D. Ostrow, S. Michaels, S.R. Friedman, E. Laumann
United States

13:10 **A prospective study of risk compensation following male circumcision as an HIV prevention method in Nyanza province, Kenya: interim results**

N. Westercamp¹, R.C. Bailey¹, K. Agot²
¹United States, ²Kenya

13:15 **What impedes universal access for women in India? A study of female sex workers in Pune**

M. Das, P. Nanda, S. Banker, R. Singh, S. Mukherjee, H. Nayak, E. Sarin
India

13:20 **Baseline prevalence of HIV/STI and changes resulting from randomized interventions among male and female migrant construction workers in Shanghai, China**

L. Calzavara¹, L. Kang², H. Fang², R. Remis¹, H. Wang², L.X. Xu², M. Yang², J. Ren², L. Light¹, T. Myers¹, Q.-C. Pan², Canada-China Team
¹Canada, ²China

13:25 **Moderated discussion**

WEPDB02 TB and Only TB

Oral Poster Discussion

Venue: Mini Room 4

Time: Wednesday 20 July, 13:00-14:00

Co-Chairs: Cissy Kityo Mutuluza, Uganda

Maryline Bonnet, Switzerland

13:00 **Lack of identification of adult TB contacts in infants with microbiologically confirmed or clinically presumed TB (MCCP TB) in clinical trial P1041**

S. Nachman¹, B. Zeldow¹, S. Dittmer², E. Krzesinski², M. Archary², P. Jean-Philippe¹, L. Mofenson¹, A. Violaro², P1041 Study Team
¹United States, ²South Africa

13:05 **Causes of death and risk factors of mortality in HIV-infected patients treated for tuberculosis enrolled in the CAMELIA trial (ANRS 1295/12160 – CIPRA KH001/10425)**

Q. Marcy¹, D. Laureillard^{1,2}, S. Chan¹, Y. Madec³, C. Mayaud³, L. Borand¹, N. Prak¹, C. Kim¹, K.K. Lak¹, C. Hak¹, B. Dim¹, T. Sok¹, A.E. Goldfeld^{1,4}, F.X. Blanc³
¹Cambodia, ²Viet Nam, ³France, ⁴United States

13:10 **Prevalence of multi-drug resistant mycobacterium tuberculosis (MDRTB) among patients admitted to the Bwaila-Kamuzu Central Hospital (KCH) Inpatient Tuberculosis Ward, Lilongwe, Malawi**

C.K. Vorkas^{1,2}, D.L. Kayira¹, R. Krysiak¹, C. Kanyemba¹, T. Chikaonda¹, N. Nguluwe¹, M. Kalikhoka¹, D. Kalaundi¹, D. Namarika¹, F. Martinson^{1,2}, C. van der Horst^{1,2}, I. Hoffman^{1,2}, M. Hosseinipour^{1,2}
¹Malawi, ²United States

13:15 **CD4-specific rates of death and tuberculosis among HIV-infected adults prior to antiretroviral treatment with high CD4 counts in West Africa**

C. Lewden¹, D. Gabillard¹, A. Minga², E. Messou², D. Ekouevi², I. Konate³, B. Tonwe-Gold³, A. Ouedraogo³, V. Leroy¹, F. Dabis¹, C. Laurent¹, X. Anglaret^{1,2}, the ANRS 12222 Morbidity/Mortality Study Group
¹France, ²Cote D'Ivoire, ³Burkina Faso

13:20 **Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries**

S. Lodi¹, A. d'Arminio Monforte², J. del Amo³, S. Abregall⁴, C. Sabin¹, K. Porter¹, E. Girardi², on behalf of the CASCADE Collaboration
¹United Kingdom, ²Italy, ³Spain, ⁴France

13:25 **High prevalence of subclinical tuberculosis in HIV-1 infected persons without advanced immunodeficiency: implications for TB screening**

T. Oni^{1,2}, R. Burke², R. Tsekela¹, N. Bangani¹, R. Seldon¹, H.P. Gideon¹, K. Wood¹, K.A. Wilkinson^{1,2}, T.H. Ottenhoff², R.J. Wilkinson^{1,2}
¹South Africa, ²United Kingdom, ³Netherlands

13:30 **Moderated discussion**

Wednesday 20 July
14:30-16:00

WEBS01 Drug Resistance: A Bridge from Basic to Operations Research
Bridging Session

Venue: Session Room 1

Time: Wednesday 20 July, 14:30-16:00

Co-Chairs: Carlo Federico Perno, Italy
Charles Boucher, Netherlands

The issue of resistance still stands as a major factor able to limit the efficacy of antiviral drugs, as well as to control the spread of the virus to uninfected persons. This is particularly true for developing countries, where there is a limited availability of potent antiviral combinations, as well as a shortage of laboratories skilled enough to assess on a routine basis the resistance in patients undergoing treatment. This is also true, though for slightly different reasons, in developed countries, where the assessment of the best long-term therapy for each single person goes through the deep evaluation of the characteristics of both the virus and the host. Under these circumstances, there is still a major need of information regarding the spread of resistance over the world, as well as the implementation of procedures and activities, at national and international level, able to support the effort of improving at best the therapeutic strategies both for adults and children. The upcoming routine availability of new and exciting technologies, such as the deep sequencing, may let scientists and clinicians improve the tailoring of therapy to each single patient, by selecting those drugs and strategies able to hit at best the virus of each particular patient. For these reasons, this bridging session mandatorily requires competence and expertise of scientists, clinicians and policy makers able to set the stage of the intervention in this key field.

14:30 **Introduction**

14:35 **Pathogenesis of HIV resistance: current knowledge and new methodologies**

F. Ceccherini Silberstein, Italy

14:50 **Clinical relevance of HIV resistance in developed and developing countries and therapeutic strategies**

D. Kuritzkes, United States

15:05 **Epidemiology of HIV resistance and strategies to prevent spreading**

A. Tanuri, Brazil

15:20 **Containing resistance spread: operational research and implementation**

S. Bertagnolio, Switzerland

15:35 **Questions and answers**

15:55 **Conclusion**

WEAB01 Emerging Trends in HCV/HIV Co-Infection

Oral Abstract Session

Venue: Session Room 2

Time: Wednesday 20 July, 14:30-16:00

Co-Chairs: Phyllis Tien, United States
Adeeba Kamarulzaman, Malaysia

14:30 **Temporal trends in liver-related mortality in a prospective cohort of HIV-infected patients in Spain, 1997-2008**

J. Berenguer, B. Alejos, V. Hernando, P. Viciano, J.A. Oteo, J.L. Gómez Sirvent, D. Dalmau, J. Portilla, S. Moreno, J. Del Amo, and CoRIS Spain

14:40 **Mixed HCV genotypes infection and response to anti-HCV treatment in HIV/HCV co-infected patients**

L. Porrino, S. Bagaglio, G. Morsica, G. Gallotta, H. Hasson, L. Galli, V. Rusconi, A. Lazzarin, C. Uberti-Foppa Italy

14:50 **Utility of enhanced liver fibrosis (ELF) marker as a non-invasive predictor of mortality in HIV/HCV-co-infected women from the Women's Interagency HIV Study (WIHS)**

*M. Peters¹, P. Bacchetti¹, R. Boylan¹, A. French¹, P. Tien¹, M. Plankey¹, M. Glesby¹, M. Augenbraun¹, E. Golub¹, R. Karim¹, J. Parkes², W. Rosenberg², Women's Interagency HIV Study (WIHS)
¹United States, ²United Kingdom*

15:00 **Progressive liver histological improvement after sustained virological response to therapy in HCV/HIV co-infected patients**

J.L. Casado, P. Martí-Belda, C. Quereda, M. del Palacio, A. Moreno, M. Pumares, M.J. Pérez-Eliás, S. Moreno Spain

15:10 **Maraviroc (MVC) reduces liver stiffness (LS) in HIV-hepatitis C (HCV) co-infected patients**

P. Nasta, F. Gatti, F. Borghi, S. Amadasi, E. Chiari, A.M. Paderno, G. Carosi Italy

15:20 **Moderated discussion**

WELBX Late Breaker Cross-Track A/B

Oral Abstract Session

Venue: Session Room 3

Time: Wednesday 20 July, 14:30-16:00

- 14:30 **Biomarkers of inflammation, coagulation and liver fibrosis are associated with hepatic flares and death in HIV hepatitis co-infected persons**
B. Andrade¹, K. Huppler Hullsiek¹, D. Boulware¹, A. Rupert¹, M. French², K. Ruxrungtham³, M. Montes⁴, H. Price⁵, P. Barreiro⁴, J. Audsley², S. Lewin², I. Sereti¹, INSIGHT
¹United States, ²Australia, ³Thailand, ⁴Spain, ⁵United Kingdom
- 14:40 **Cerebrospinal fluid (CSF) drug resistant HIV compartmentalization detected during primary HIV-1 infection by ultra deep sequencing**
A. Gega, M. Kozal, J. Chiarella, E. St John, B. Simen, E. Lee, J. Peterson, R. Price, S. Spudich
 United States
- 14:50 **Depletion of naïve CD4⁺T cell compartment by immune hyperactivation can be rapidly reversed by AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs)**
D.V. Baev¹, D. De Forni¹, E. Katabira², R. Maserati¹, P. Cahn³, B. Poddesu¹, M.R. Stevens⁴, F. Lori¹
¹Italy, ²Uganda, ³Argentina, ⁴United States
- 15:00 **Analysis of resistance associated variants by HCV genotype 1 subtype (1a/1b) in phase 3 (SPRINT-2/RESPOND-2) boceprevir plus standard of care clinical trials**
D. Hazuda, R. Ogert, J. Howe, R. Barnard, J. Strizki, C. Brass, M. Burroughs, N. Boparai, J. Albrecht, A. Howe
 United States
- 15:10 **Results of the CARINEMO-ANRS 12146 randomized trial comparing the efficacy and safety of nevirapine versus efavirenz for treatment of HIV-TB co-infected patients in Mozambique**
M. Bonnet¹, N. Bhatt², E. Baudin³, C. Silva², C. Michon³, A.-M. Taburet³, L. Ciaffi¹, A. Sobry², R. Bastos², E. Nunes², A. Barreto², C. Rouzioux³, I. Jani², A. Calmy¹, CARINEMO study group
¹Switzerland, ²Mozambique, ³France
- 15:20 **The effect of short-course ART initiated in primary HIV-1 infection on IL-6 and D-dimer: results from SPARTAC, an international randomised controlled trial**
E. Hamlyn¹, F. Ewings¹, K. Porter¹, D.A. Cooper², M. Fisher¹, G. Tambussi³, M. Schechter⁴, J.M. Miro⁵, A. Babiker¹, J. Weber¹, M. McClure¹, S. Fidler¹, SPARTAC study investigators
¹United Kingdom, ²Australia, ³Italy, ⁴Brazil, ⁵Spain

WEWS02 Implementation and Operations Research Considerations for Rolling Out the 2010 WHO Guidelines on PMTCT and Infant Feeding
Venue: Mini Room 1
Time: Wednesday 20 July, 14:30-17:30
Co-Facilitators: Laura Guay, United States
 Christian Pitter, United States

Level: Intermediate
 Target Audience: Researchers, Programme Managers, Health Care Providers, Policy Makers
 Seating Limit: 50
 This workshop will provide insight into the implementation and operational research considerations related to scale-up of the revised World Health Organization (WHO) guidelines on PMTCT. The workshop will specifically focus on the infant feeding guidelines.

WEWS03 Towards an HIV Cure: Insight into Residual Viral Replication, Establishment of Reservoirs and Understanding Mechanism of Persistence
Venue: Mini Room 2
Time: Wednesday 20 July, 14:30-17:30
Co-Facilitators: Christine Rouzioux, France
 Nicolas Chomont, United States

Level: Intermediate
 Target Audience: Undergraduate and Postgraduate Students, Postdoctoral Fellows, Biology and Pathogenesis Researchers, Clinicians
 Seating Limit: 100
 The purpose of the workshop is to provide participants with the knowledge and skills they need to begin or pursue their research on HIV persistence and viral reservoirs. International experts will present state of the art and future challenges in the field. Several areas will be covered, including immunological and virological mechanisms of persistence, tools to measure viral reservoirs, animal models and therapeutic strategies aimed at eradicating HIV. Presentations will focus on practical information pertaining to viral reservoirs (including methods, samples and description of cohorts). In addition, speakers will provide the audience with the background information needed to undergo lab research on the topics of viral persistence, latency and eradication.

WEAD01 Moving Towards Decentralization of HIV Services
Oral Abstract Session
Venue: Mini Room 3
Time: Wednesday 20 July, 14:30-16:00
Co-Chairs: Giampiero Carosi, Italy
 Charles Kouanfack, Cameroon

- 14:30 **Decentralization of laboratory testing capacity in resource-limited settings: seven years of experience in six African countries**
F. Marinucci, S. Medina-Moreno, A. Paterniti, M. Wattleworth, R. Redfield
 United States
- 14:40 **The role of primary health facilities (PHF) in expanding pediatric care and treatment services in Sub-Saharan Africa**
R. Fayorsey¹, S. Saito¹, R.J. Carter¹, E. Gusmao², K. Frederix³, E. Koeh-Keter⁴, G. Tene⁵, M. Panya⁶, E.J. Abrams¹
¹United States, ²Mozambique, ³Lesotho, ⁴Kenya, ⁵Rwanda, ⁶Tanzania, United Republic of

- 14:50 **Access gains and losses of 'down-referral': decentralisation of patients taking antiretroviral therapy from hospitals to primary health care centres in rural South Africa**
M. Moshabela¹, H. Schneider¹, S. Cleary¹, P. Pronyk², J. Eyles³
¹South Africa, ²United States, ³Canada
- 15:00 **Positive change in recruitment rate and baseline characteristics but no improvement in retention on anti-retroviral treatment after decentralization to health centers: an observational cohort-assessment from 2006 to 2010 in rural Lesotho**
N.D. Labhardt¹, M. Sello¹, J.S. Emmel¹, M. Motlomelo¹, T. Gass², K. Pfeiffer², M.A. Mohlaba¹, J. Ehmer²
¹Lesotho, ²Switzerland
- 15:10 **Implementation of resistance testing on dried blood spots enables individual patient management in rural settings**
R. Schuurman¹, H. Tempelman¹, S. Aitken¹, P. Schrooders², M. Slabbert², A.M.J. Wensing¹
¹Netherlands, ²South Africa
- 15:20 **Moderated discussion**

WEAX02 Integration of Reproductive Health and HIV: Promoting Choice, Access and Reducing Risk

Oral Abstract Session

Venue: Mini Room 4

Time: Wednesday 20 July, 14:30-16:00

Co-Chairs: Mary Pat Kieffer, Swaziland
 Enrico Girardi, Italy

14:30 **Introduction**

- 14:35 **Comparing two strategies for enrolling HIV-infected pregnant women from antenatal care to care and treatment services in Cameroon: Continuum of Care Operations Research (CORE) study**
P. Tih¹, E. Nshom¹, E. Onyoh¹, C. Harrington¹, Z. Fox², J. Nkfusai¹, E. Kuni¹, E. Mboh¹, D. Palmer¹, T. Welty¹
¹Cameroon, ²United Kingdom

- 14:45 **Using facilitated referrals to integrate family planning into HIV care and treatment clinics in Tanzania**
M.S. Green¹, M.A. Weaver¹, T.W. Koh², S.N. Mujaya², C. Lasway², G. Mpagile², J.N. Baumgartner¹
¹United States, ²Tanzania, United Republic of

- 14:55 **Integration of ART in MCH settings: the way forward for increasing access to ART for eligible HIV-positive pregnant women in Zimbabwe**
A. Muchedzi, T. Nyamundaya, B. Makunike-Chikwinya, A. Mushavi, R. Mugwagwa
 Zimbabwe

- 15:05 **Unplanned pregnancies and family planning uptake among HIV-positive women in Mwanza City, Tanzania**
R. Balira¹, K. Jackson¹, D. Mabey², D. Ross², D. Watson-Jones^{1,2}, H. Weiss²
¹Tanzania, United Republic of, ²United Kingdom

- 15:15 **Contraceptive eligibility, choice and acceptance of the copper intrauterine device (IUD) among HIV+ clients at an ART clinic in Lilongwe, Malawi**
L. Haddad¹, M. Nyirenda², C. Cwiak¹, H. Tweya², C. Feldacker², D. Jamieson¹, M. Hosseinipour^{1,2}, I. Hoffman¹, A. Bryant¹, G. Stuart¹, I. Noah², L. Mulundila², B. Samala², S. Phiri²
¹United States, ²Malawi

- 15:25 **Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis**
R. Heffron¹, D. Donnell¹, H. Rees², C. Celum¹, E. Were³, N. Mug³, G. de Bruyn², E. Nakku-Joloba⁴, K. Ngure³, J. Kiarie³, J. Baeten¹
Partners in Prevention HSV/HIV Transmission team
¹United States, ²South Africa, ³Kenya, ⁴Uganda

15:35 **Moderated discussion**

15:55 **Conclusions**

Wednesday 20 July
 16:30-17:30

WELBB Late Breaker Track B

Oral Abstract Session

Venue: Session Room 1

Time: Wednesday 20 July, 16:30-17:30

- 16:30 **Risk of progression to AIDS or death in relation to CD4 cell levels in HIV-infected adults with a suppressed viral load under cART**
H.C. Bucher, J. Young, on behalf of COHERE
 Switzerland

- 16:40 **Impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study**
B. Durovni¹, V. Saraceni¹, A. Pacheco¹, S. Cavalcante¹, S. Cohn², B. King², L. Moulton², R. Chaisson², J. Golub², THRio study group
¹Brazil, ²United States

- 16:50 **SWIFT study: switching from lamivudine/abacavir (3TC/ABC) to emtricitabine/ tenofovir DF (FTC/TDF) maintained efficacy and reduced virologic failure**

R. Campo, E. DeJesus, H. Khanlou, H. Wang, K. White, L. Dau, J. Flaherty, T. Fralich
United States

- 17:00 **Evaluation of a novel point of care cryptococcal antigen (CRAG) test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis**
J.N. Jarvis^{1,2}, A. Percival³, S. Bauman³, G. Meintjes^{1,2}, G.N. Williams², N. Longley^{1,2}, T. Harrison¹, T. Kozel³
¹United Kingdom, ²South Africa, ³United States
- 17:10 **Elvitegravir once-daily is non inferior to raltegravir twice-daily in treatment experienced patients: 48 week results from a phase 3 multicenter, randomized, double blind study**
J.-M. Molina¹, A. LaMarca², J. Andrade Villanueva³, B. Clotet⁴, N. Clumeck⁵, Y.-P. Liu², L. Zhong², A. Cheng², J. Szwarcberg², S.L. Chuck², for the Study 145 Group
¹France, ²United States, ³Mexico, ⁴Spain, ⁵Belgium

WELBC Late Breaker Track C
Oral Abstract Session

Venue: Session Room 2

Time: Wednesday 20 July, 16:30-17:30

- 16:30 **Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study**
M.C. Thigpen¹, P.M. Kebaabetswe², D.K. Smith¹, T.M. Segolodi², F.A. Soud¹, K. Chillag¹, L.I. Chirwa², M. Kasonde², R. Mutanhaurwa², F.L. Henderson¹, S. Pathak¹, R. Gvetadze¹, C.E. Rose¹, L.A. Paxton¹, for the TDF2 Study Group
¹United States, ²Botswana
- 16:40 **Effect of the Orange Farm (South Africa) male circumcision roll-out (ANRS-12126) on the spread of HIV**
B. Auvert¹, D. Taljaard², D. Rech², P. Lissouba¹, B. Singh², D. Shabangu², C. Nhlapo², J. Otchere-Darko², T. Mashigo², G. Phatedi², R. Taljaard², M. Tsepe², M. Chakela², A. Mkhwanazi², P. Ntshangase², S. Billy², D. Lewis²
¹France, ²South Africa
- 16:50 **Pooled analysis of five randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission**
M. Hudgens¹, T. Taha¹, S.B. Omer¹, D.J. Jamieson¹, H. Lee¹, L.M. Mofenson¹, C. Chasela², A.P. Kourtis¹, N. Kumwenda¹, A. Ruff⁴, A. Bedri Kelo³, B. Jackson¹, P. Musoke¹, R.C. Bollinger¹, N. Gupte⁴, M.C. Thigpen¹, A. Taylor¹, C. van der Horst¹
¹United States, ²Malawi, ³Ethiopia, ⁴India
- 17:00 **Completed observation of the randomized placebo-controlled phase of iPrEx: daily oral FTC/TDF pre-exposure HIV prophylaxis among men and trans women who have sex with men**
R. Grant¹, V. McMahan¹, A. Liu¹, J. Guanira², M. Casapia², J. Lama², T. Fernandez³, V. Veloso⁴, S. Buchbinder¹, S. Chariyalertsak⁵, M. Schechter⁴, L.-G. Bekker⁶, K. Mayer¹, E. Kallas⁴, P. Anderson¹, K.R. Amico¹, D. Glidden¹, for the iPrEx Study Team
¹United States, ²Peru, ³Ecuador, ⁴Brazil, ⁵Thailand, ⁶South Africa
- 17:10 **Prevalence of serodiscordance, seropositivity, and exclusionary factors in US male couples presenting for Couples Voluntary Counseling and Testing (CVCT): preliminary results**
P. Sullivan¹, R. Stephenson¹, L. Salazar¹, M. Mann¹, J. Barnes¹, L. Scales¹, S. Allen¹
United States

WELBD Late Breaker Track D
Oral Abstract Session

Venue: Session Room 3

Time: Wednesday 20 July, 16:30-17:30

- 16:30 **Taking the first steps in national GeneXpert implementation: lessons learned from South Africa**
W. Stevens¹, N. Gous¹, L. Erasmus¹, G. Coetzee¹, B. Cunningham¹, L. Scott¹
South Africa
- 16:40 **Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa**
J.N. Jarvis^{1,2}, T. Harrison¹, S. Lawn^{1,2}, G. Meintjes^{1,2}, R. Wood², S. Cleary²
¹United Kingdom, ²South Africa
- 16:50 **"Analyze locally & act locally": geographical prioritization of districts/blocks and strategic approach using data triangulation in Gujarat, India**
L. CHAVAN¹
India
- 17:00 **Risk factors for loss to follow-up prior to ART initiation among HIV patients enrolling with CD4+ cell count >200 cells/uL in the multi-country MTCT-Plus initiative**
R.C. Gwynn¹, A. Fawzy¹, I. Viho², Y. Wu¹, E. Abrams¹, D. Nash¹
¹United States, ²Cote D'Ivoire
- 17:10 **Evaluation of a point of care-CD4 testing in Ethiopia**
B. TEGBARU¹, T. Messele¹, A. Abebe¹, D. Teshome¹, E. Hailu¹, F. Challa¹, H. Hailu¹, Y. Alemayehu¹
Ethiopia

WELBA Late Breaker Track A
Oral Abstract Session

Venue: Mini Room 4

Time: Wednesday 20 July, 16:30-17:30

- 16:30 **Cell-based measures of viral persistence are associated with immune activation and PD-1+-expressing CD4+ T cells**
H. Hatano, V. Jain, P. Hunt, J. Martin, T.-H. Lee, E. Sinclair, J. Mccune, M. Busch, S. Deeks
 United States
- 16:40 **Naïve T cell recruitment is not required for the stability of CD4⁺ memory T cell homeostasis in progressive SIV infection**
A. Okoye, M. Rohankhedkar, C. Abana, A. Pattenn, M. Reyes, C. Pexton, A. Slywester, R. Lum, S. Planer, A. Legasse, M. Piatak, J. Lifson, M. Axthelm, L. Picker
 United States
- 16:50 **Memory CCR6+CD4+ T-cells are selectively imprinted with a transcriptional program favorable to productive HIV-1 infection**
P. Monteiro¹, J.-P. Goulet², A. Gosselin¹, V.S. Wacleche¹, M.-R. Boulassel¹, J.-P. Routy¹, N. Grandvaux¹, E. Haddad², R.-P. Sekaly^{1,2}, P. Ancuta¹
¹Canada, ²United States
- 17:00 **Nucleoprotein 62 interacts with HIV-1 integrase and contributes to viral integration**
Z. Ao, K. Danappa Jayappa, B. Wang, X. Yao, Laboratory of Molecular Human Retrovirology
 Canada
- 17:10 **HIV associated lymphadenopathy and dysregulation of T-cell egress related to diminished sphingosine phosphate receptor expression and activity**
J. Mudd¹, R. Debernardo¹, C. Kityo², J. Chipman¹, G. Beilman¹, B. Rodriguez¹, N. Funderburg¹, T. Schacker¹, S. Sieg¹, M. Lederman¹
¹United States, ²Uganda

Wednesday 20 July
 18:00-19:30

-
- WEPL02 Rapporteur and Closing Session**
Plenary
- Venue:** Session Room 1
Time: Wednesday 20 July, 18:00-19:30
Chair: Bertrand Audoin, Switzerland
- 18:00 **Track A Rapporteur Report**
G. Marchetti, Italy
- 18:15 **Track B Rapporteur Report**
- 18:30 **Track C Rapporteur Report**
A. Adimora, United States
- 18:45 **Track D Rapporteur Report**
C. Makhoulf Obermeyer, Switzerland
- 19:00 **Community Statement**
A. Cerioli, Italy
- 19:10 **Keynote Address**
- 19:20 **Closing Remarks**
E. Katabira, Uganda
S. Vella, Italy
- 19:25 **See you in Kuala Lumpur!**
A. Kamarulzaman, Malaysia